Podcasts about Sanofi Pasteur

What if your dentist could spot cavities long before they became a problem? Join us as we chat with Jordan Rubinson, CEO of CaviSense, about his interesting journey from pharma to medtech  We start by discussing Jordan's early influences, from his father's career at Block Drug Company to his own academic adventures at Columbia and MIT's Sloan School. Despite an initial interest in accounting, Jordan's passion for pharma led him down a path less traveled, avoiding the conventional business routes of consulting and investment banking.Next, we take a closer look at Jordan's dynamic career in the pharmaceutical industry. Learn how his family's frequent relocations led to professional opportunities across the globe. Jordan shares  anecdotes from his time in big pharma, including his experiences within a management development program at Sanofi Pasteur  and the challenges of managing diverse roles in different markets. His shift from big pharma to the innovative medtech startup scene in Israel provides a compelling narrative about the contrasts between structured environments and the fast-paced, resource-tight nature of startups.Finally, we explore the evolving role of dentists as both medical professionals and entrepreneurs. Discover how new technologies  are revolutionizing dental care, especially in pediatric dentistry. Jordan introduces us to CaviSense, a groundbreaking tool for early cavity detection, and discusses its journey from early development to FDA registration. We also touch on the exciting future of consumer-friendly dental monitoring tools that could transform how we manage oral health at home. Don't miss this episode to hear about the future of interactive dental care and the potential for improved patient outcomes.Host David E. Williams is president of healthcare strategy consulting firm Health Business Group. Produced by Dafna Williams.

The World Health Organization recently authorized a second dengue vaccine. The move could provide protection for millions of people worldwide against the mosquito-borne disease. 世界卫生组织最近批准了第二种登革热疫苗。此举可以为全世界数百万人提供保护，使其免受蚊媒疾病的侵害。 This year, several dengue outbreaks have happened in places across the Americas. 今年，美洲各地爆发了多起登革热疫情。 In a statement on May 15, the U.N. health agency said it approved the dengue vaccine made by the Japanese drugmaker Takeda. 联合国卫生机构在5月15日的一份声明中表示，批准了日本制药商武田公司生产的登革热疫苗。 Takeda's dengue vaccine is known as Qdenga. It was previously approved by the European Medicines Agency in 2022. The two-dose vaccine is given three months apart. It protects against the four kinds of dengue. The WHO recommends its use in children between the ages of 6 and 16 who live in areas with high rates of dengue. 武田的登革热疫苗被称为 Qdenga。此前该疫苗已于 2022 年获得欧洲药品管理局批准。两剂疫苗间隔三个月接种。它可以预防四种登革热。世界卫生组织建议居住在登革热高发地区的 6 至 16 岁儿童使用该药物。 Approval by the WHO now means that donors and other U.N. agencies can purchase the vaccine for poorer countries. 世界卫生组织的批准现在意味着捐助者和其他联合国机构可以为较贫穷的国家购买疫苗。 Studies have shown Takeda's vaccine is about 84 percent effective in preventing people from being hospitalized and about 61 percent effective in stopping symptoms. 研究表明，武田的疫苗在预防人们住院方面的有效性约为 84%，在阻止症状方面的有效性约为 61%。 WHO's Rogerio Gaspar is director for the agency's approvals of medicines and vaccines. He said it was “an important step in the expansion of global access to dengue vaccines.” 世卫组织的罗杰里奥·加斯帕 (Rogerio Gaspar) 是该机构药品和疫苗审批主管。他表示，这是“扩大全球登革热疫苗获取范围的重要一步”。The first dengue vaccine that the WHO approved was made by the drugmaker Sanofi Pasteur. The vaccine was later found to increase the risk of severe dengue in people who had not been infected with the disease before. 世界卫生组织批准的第一种登革热疫苗是由制药商赛诺菲巴斯德生产的。后来发现该疫苗会增加以前未感染过这种疾病的人患严重登革热的风险。 There is no exact treatment for dengue. It is a leading cause of serious illness and death in about 120 Latin American and Asian countries. About 80 percent of infections are mild. But severe cases of dengue can lead to internal bleeding, organ failure, and death. 登革热没有确切的治疗方法。它是大约 120 个拉丁美洲和亚洲国家严重疾病和死亡的主要原因。大约 80% 的感染是轻微的。但严重的登革热病例会导致内出血、器官衰竭和死亡。 Last week, the WHO reported there were 6.7 million suspected cases of dengue in the Americas. That is an increase of 206 percent compared with the same period last year. In March of this year, officials in Rio de Janeiro declared a public health emergency over its dengue epidemic. Brazilian health officials began giving out the Takeda vaccine with the goal of protecting at least 3 million people. 上周，世界卫生组织报告美洲有 670 万疑似登革热病例。与去年同期相比增长了 206%。今年3月，里约热内卢官员宣布登革热疫情进入公共卫生紧急状态。巴西卫生官员开始分发武田疫苗，目标是保护至少 300 万人。 Infectious disease experts say climate change and the increased range of mosquitoes that carry dengue are partly to blame for the spread of the disease. 传染病专家表示，气候变化和携带登革热的蚊子数量的增加是造成这种疾病传播的部分原因。

Pfizer Inc. v. Sanofi Pasteur Inc.

Na infekcijskih oddelkih slovenskih bolnišnic zdravijo vedno več bolnikov, ki so okuženi z novim koronavirusom. Sicer smo pri nas zaznali že tudi gripo, med otroci pa kroži predvsem respiratorni sincicijski virus (RSV). Glede sezonskih okužb sicer ne odstopamo od sosednjih in drugih evropskih držav. Izstopa pa Hrvaška – in to po številu primerov oslovskega kašlja. Do prejšnjega petka (22.12.23) so zabeležili že 3805 primerov – in to v vseh starostnih skupinah. Tamkajšnjo situacijo skrbno spremljajo tudi slovenski epidemiologi in infektologi. Med njimi je tudi dr. Tanjo Selič Kurinčič, ki jo je v Splošno bolnišnico Celje poklical Iztok Konc. Foto: Alain Grillet, Sanofi Pasteur, cc

Why did I decide to encore this show about being customer-centric and transforming or innovating at a very large organization? Well, two main reasons. First reason can be neatly summed up by this recent Tweet from Rik Renard, which I have edited slightly to suit my own purposes. Here's the Tweet: “The Achilles' heel for most healthcare [innovators] is overlooking the role of change management. The deal isn't sealed until the whole team is raving. Adoption doesn't [automatically follow innovative thoughts no matter how good they are or how much it cost to build or buy anything]. Take change mgmt seriously.” This is relevant to pharma companies, to big provider organizations, to SaaS vendors, to payers … pretty much anyone. So, yeah. This show … still relevant. But also there's a #2 reason for this encore. It's coming at ya smack in the middle of an ongoing series for boards of directors, CEOs, and CFOs of self-insured employers. As discussed last week in the show with Mark Cuban and Ferrin Williams, PharmD, MBA (EP418), healthcare has become financialized. There is a whole financial layer sitting in between health benefits and the employer, and dealing with that requires customer centricity, transformation, and innovation at the employer level—a little change management, if you will. And with that, here is your encore. I was at the PanAgora Pharma Customer Experience (CX) Summit. Let me tell you one of my big takeaways. Many at pharma companies who are trying to convince their organizations of the need to be provider- and/or patient-centric are having a tough go of it. Heard that coming from every direction. Seems there are quite a few pharma organizations out there who are not actually customer/patient-centric. Say it isn't so. Turns out, they continue to be pretty darn brand-centric whether or not anyone besides the CX team and the most successful KAMs (key account managers) realize this hard truth. This matters because, from a provider organization, physician, or patient standpoint, it's not what's written on the walls … it's what goes on in the halls. It's what a company actually does in their interactions with the rest of the healthcare ecosystem that matters and that builds their reputation. You see this lack of customer centricity and, et cetera et cetera, there are certainly other things going on here; but you see the lack of customer centricity manifesting, right? You see the pharma reps that get kicked out of hospital systems because the perception is they add little if any value and “waste doctors' time; all they do is shove detail aids in our faces.” Heard that recently. Look, this doesn't just pertain to Pharma; this is a message for the whole industry. But there is certainly a way to do well by doing good, and how that starts is helping provider organizations and patients improve patient outcomes as the primary goal. Being innovative to that end. It's about supporting the best-practice standard of care and bringing resources to bear that are truly helpful. That is how more of the right patients can get the right treatment/drug at the right time or take their meds as per the A1A clinical guideline. It's probably also the way to sustainable business success. I've said it here a thousand times: People trying to do the right thing by patients all need to work together. If there's a party in the mix that nobody else wants to deal with because they are deemed not a team player or they don't listen … yeah, that's what I call a competitive disadvantage, beyond just squandering their ability to achieve their mission statement and improve patient care and lives, that is. Today's conversation is with Karen Root, who was a speaker at the aforementioned PanAgora conference. In this healthcare podcast, we are talking about how to make transformation and innovation actionable at a large organization—maybe a pharma company but pretty much any large organization with lots of people, lots of human beings with different motivations and goals. As we all know, for every early adopter, there are (it feels like) five laggards who will fight you tooth and nail because they do not want to transform. They like being brand-centric, and it's been working out fine … well, up until this year, at least. Karen Root is currently director of experience strategy at Boehringer Ingelheim, which is a pharma company. For many years prior to her current role, she was an enterprise head of brand and culture at WL Gore & Associates. What we talk about in this show is how to break down the historical “brand is king” mentality so that people want to follow with the awareness, courage, and determination to do so. Everything that we talk about in this episode can also be applied to pretty much any organizational transformation or the rollout of any innovation or new capability. Here's the key things that Karen talks about which are essential for an organization to transform, maybe (again) in a way that is customer-centric and/or to roll out new innovations or capabilities: 1. Leaders must communicate a compelling vision that also includes a realistic assessment of what it's gonna take to reach that vision and offer hope and the promise that the hard work and inevitable problems will all be worth it. 2. Systems thinking—a consideration of the systems and the people who will need to be a part of the transformation, thinking through what is likely to go wrong and proactively planning for it 3. Identify the right entry point. This should be a micro-journey or a quick win so that the team can score a victory and get through the messy middle that exists in any transformation or rollout. Triple points if you can find a micro-moment that has some emotionality connected to it from your customers' perspective or patient perspective. If you can fix a so-called moment that matters, it really matters. Consider starting by looking into call center logs, finding a common complaint, and fixing it. Do it this way and it's harder for anybody to complain that the status quo is so super amazing and tell you to talk to the hand. 4. Determine how you are going to measure what your quick win accomplished, as well as your whole larger transformational effort. 5. Ensure you have a full story arc here that shows the before and the after that clearly articulates that the before (the status quo) is problematic and that we have to, with urgency, get to the after. 6. Never forget that we're working with human beings here and not, as they say, rational economic actors. One heads-up: In the conversation with Karen today, we talk a lot about the so-called J curve. As Karen says (and you can look this up), whenever you introduce a new anything into an organization, at some point, there's gonna be a mess-up. And when something messes up, the whole team will spiral into a so-called “trough of disillusionment” or a “trough of despair,” sometimes it's called. This is the rock-bottom hook of that J in the J curve. The thing is, if a leader's vision isn't sufficient or their will to continue isn't sufficient, then the organization quits at this low point instead of working through it and coming out in a better place on the other side of the J. And you know what happens then. From that point forward until eternity, everybody who brings up implementing an innovation or a transformation will definitely hear the lecture about the time we tried that and how it failed miserably. So, the J curve … Check it out. Don't underestimate it. One very last thing: If you are working for a large organization (like Fortune 500 large) and you have succeeded in moving a transformation forward (like being actually patient-centric or customer-centric, for example), hit me up. I would certainly love to hear your thoughts on how you did it and why you think you were successful and the impact that you had.   You can learn more by connecting with Karen on LinkedIn.     Karen Root, MBA, CCXP, is a strategy, innovation, operations, and marketing executive with more than two decades of experience in healthcare, including medical devices, biopharma, and pharmaceuticals. Her background spans more broadly to include computer software, publishing, and consumer package goods. She has driven transformation and growth as a senior executive for companies ranging from start-ups to Fortune 100 multinational organizations. Driving transformative capabilities include digital marketing for Sanofi Pasteur and marketing at start-up for their subsidiary, VaxServe. Karen then led the medical division in customer experience at WL Gore & Associates, later leaving the organization as enterprise leader of brand and culture. She is currently leading customer experience in the United States for Boehringer Ingelheim. Karen has been adding innovative experience design in the metaverse to her arsenal of knowledge. Certified in blockchain technology, cryptocurrency, non-fungible tokens (NFTs), and as a metaverse expert, she has a patent pending in smart contracts and is exploring integrating NFTs and meta-realities into the healthcare space. Karen is the author of Spectrum Thinking and Signature Experience: The Intersection of Brand Promise and Customer Experience for Competitive Advantage. Her next book, Ready Worker One, was co-written with her daughter, Kayla Root, and is expected to be published in early 2024. It pulls from gaming and behavioral science, along with DAO structure (decentralized, autonomous organizations). Karen was recognized by Forbes in 2022 as one of the Top 10 Healthcare Entrepreneurs to Watch.   08:51 What skills does leading a large company in customer centricity require? 10:36 What needs to be included in a vision for customer-centric change? 11:01 “In transformation, we have to adjust the approach to that vision. We have to break it down into a couple of key steps.” 11:39 What is the J curve? 12:26 “Disruption is going to happen; it's just how do we minimize its impact.” 14:00 Why is hope so important for success in change? 17:22 “Leverage your people; understand where they are in the change curve.” 26:24 “We can't manage what we don't measure.” 26:33 “We have to not only measure in quantitative ways but qualitative.” 27:35 What's the downside to not being able to innovate? 28:55 Why does leadership need to have a story to tell? 31:19 “We have to remember that these are human beings and to look for those tells.”   You can learn more by connecting with Karen on LinkedIn.   Karen Root of @boehringerus discusses #customercentricity in our #healthcarepodcast. #healthcare #podcast #digitalhealth #pharma   Recent past interviews: Click a guest's name for their latest RHV episode! Mark Cuban and Ferrin Williams, Dan Mendelson (Encore! EP385), Josh Berlin, Dr Adam Brown, Rob Andrews, Justina Lehman, Dr Will Shrank, Dr Carly Eckert (Encore! EP361), Dr Robert Pearl, Larry Bauer (Summer Shorts 8)  

In this episode of Real Time with WLP, Emma Charles, Senior Vice President- Intercontinental Markets, Bristol Myers Squibb and Cindy Woodcock from the WLP Mentoring Committee and Program Lead, Stakeholder Engagement at Canadian Institute for Health Information (CIHI), talk about "The Critical Role of Authenticity as a Mentor". Emma describes what authenticity means to her and how it contributes to building positive relationships between mentors and mentees. We explore the “What If” approach and its impact on fostering authentic connections. Emma Charles is Senior Vice President of Intercontinental Markets at Bristol Myers Squibb. In this role, Emma oversees a diverse region, with responsibilities for 70+ markets across the world, including China, Asia, Australia, Central & Eastern Europe, Latin America, Brazil and the Middle East. Prior to becoming SVP of Intercon, Emma was Vice President, General Manager & Board Member of BMS Italy for over six years. Before joining BMS, Emma spent more than nine years at Pfizer as Central European, Turkey & Israel Cluster lead, Head of Strategy & Business Development for Europe and Regional Lead of Rare Diseases and Neurosciences for Europe. She was with Janssen in both France and the U.S., leading commercial divisions within their neurosciences business. Emma began her career at Pasteur Merieux (now Sanofi Pasteur) working within their vaccine business as Marketing Manager of South East Asia and Global Brand Manager of Vaccines. Emma is passionate about accelerating and expanding access of innovative medicines to patients and about fostering employee engagement that thrives on diversity, inclusion and a strong speak-up culture. Her biopharma career spans more than 25 years across commercial, corporate strategy and business development operations. Emma graduated from a leading French business school in Paris, in Marketing & Finance. Emma currently resides in Rome, Italy with her family.

Yesterday's guest, Bevelyn of Chaz, was arrested again, this time for not wearing a mask, along with Edmee of Manhattan and Ken Scott of the Heavenlies. And Bob Enyart reports the important development that baby body parts are not being used in the $1.6 billion dollar U.S. coronavirus vaccine contract that just went to Novavax, and that pharmaceutical giant Sanofi Pasteur has now discontinued using fetal tissue in the production of their polio vaccine. Then Bob continues his "train-up your mind" clear thinking segments using the atheist "Euthyphro's Dilemma" argument. Google ranks Bob's Christian reply #1 at kgov.com/euthyphro. Euthyphro Part 1 introduced Socrates' argument. Part 2 evaluated the Divine Command View. Part 3 introduced the Recognition View. In Part 4 the Recognition View Meets the Trinity. Today's Part 5 turns Euthyphro's Dilemma against Bertrand Russell and the atheists. To hear the full series, just click on over to kgov.com/euthyphro-1. * RSR's HCQ Updates: See rsr.org/hcq for the full list. Most recently, the Int'l Society of Infectious Diseases reports HCQ cut the death rate by half in a Henry Ford Health System study of 2,541 hospitalized patients.* COVID Vaccines: Our friends over at cogforlife.org list the COVID vaccines under development being produced morally including those from Merck, Sanofi, and from Novavax, which on July 7th received a $1.6 billion dollar U.S. vaccine contract. Those producing vaccines immorally include Moderna and Johnson & Johnson which use fetal tissue. We strongly urge everyone to boycott vaccines developed using tissue harvested from aborted unborn children. (Remember, many institutions and celebrities who have been "pro-choice" all along are now also calling to legalize infanticide, what they call after-birth abortion.) Related: Recently, pharmaceutical giant Sanofi Pasteur discontinued using fetal tissue for its polio vaccine! While many parents have other vaccine concerns this development is an important step toward moral and socially sustainable medicine.* RSR's 25 Christian COVID Conspiracies: Bob presents a list of conspiracies vs. actual pandemic insights.* "Cases Spiking" Fake News through June & July: (July Update) All of the breathless national media reporting on "spikes" in cases through June and July are nothing but fake news when delivered without context. The mainstream media, and even Fox News and many on their network including Neil Cavuto, report "spikes" without putting that data within the needed context of increased testing and especially, the long-term steady reduction in deaths Today's Video Resource: Get out of the Matrix Bob takes on a college professor and her philosophy class in a debate regarding absolutes. Who wins? The students have been taught that nothing is absolutely right or wrong, so Bob asks them if that is absolutely right. And they’ve been taught that they can only know that which their five senses have told them, so Bob asks them which of their five senses told them that. Is the lack of intellectualism in this college class representative of American higher education? You can decide as you view this video, one of Bob’s most extraordinary presentations.

An Engagement Leadership thinker and practitioner, Céline Schillinger has been recognised multiple times for her innovative engagement initiatives in the corporate world. After a plentiful business career across several continents, Céline now runs her consultancy, We Need Social. 00:37- About Céline Schillinger and her journey. I grew up in Bordeaux, France in a family passionate about art, culture and travel. I studied political science as the general interest appealed to me, but felt attracted by the pace of private business. So, I added corporate communications to my curriculum and then got my first job in a small IT business whose main market was China. This raised my interest in business operations and Asia. I left France aged 23 to look for a job in Vietnam. Overall, this has been 10 years in non-pharma businesses, in the Asia Pacific. In 2001, I joined Sanofi Pasteur, the vaccine division of Sanofi in France. Before founding We Need Social, I was Sanofi Pasteur's Global Quality Head of Innovation and Engagement. --- Support this podcast: https://podcasters.spotify.com/pod/show/tbcy/support

La Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (Anmat) autorizó el uso de una vacuna contra el dengue desarrollada por el laboratorio japonés Takeda para todas las personas mayores de 4 años, hayan cursado o no previamente la enfermedad. En ese sentido, el director de Epidemiologóa de la Nación, Carlos Giovacchini sostuvo que se trata de una herramienta más que se suma a la prevención de la enfermedad, al tiempo que llamó a mantener los cuidados y hacer las consultas pertinentes. La cartera sanitaria dijo en un comunicado que se trata de la vacuna TAK-003 y que el laboratorio japonés de referencia comenzará el proceso productivo para enviar el primer lote al país. Esta vacuna se basa en el virus del dengue 2, al que se añade ADN de los otros tres serotipos para proteger contra cualquiera de los cuatro tipos de dengue, mientras su forma de administración está compuesta por dos dosis que deben ser aplicadas con un intervalo de tres meses. "En un estudio clínico que incluyó a más de 20 mil participantes, durante 4,5 años, la vacuna demostró reducir un 84% las hospitalizaciones por dengue y un 61% los casos de dengue sintomático", indicó, por otra parte, un comunicado de prensa del laboratorio Takeda. El Ministerio indicó que la TAK-003, también conocida como Qdenga, recibió su primera aprobación en agosto de 2022 en Indonesia y posteriormente en la Unión Europea en diciembre del año pasado. Luego, le siguieron el Reino Unido en enero de 2023 y recientemente ha sido también aprobada por la Agencia Nacional de Vigilancia Sanitaria de Brasil (Anvisa). "La llegada de una nueva vacuna siempre abre una esperanza de prevenir una enfermedad y, fundamentalmente de poder prevenir el impacto más grave de la misma, sobre todo aquellos casos que pueden requerir internaciones y poner en riesgo la vida. En relación con esta vacuna contra el dengue, lleva varios años de investigación y desarrollo que permiten confirmar su seguridad y eficacia, y puede ser administrada independientemente de que la persona haya tenido o no dengue previamente", sostuvo el doctor Pablo Bonvehí, Jefe de Infectología del Hospital Universitario Cemic. "La evolución de la enfermedad causada por el dengue está relacionada con factores de la persona que se infecta y la manera que responde a la infección, el serotipo que infecta a la persona, y la consulta precoz", afirmó por su parte del doctor Eduardo López, Jefe del Departamento de Medicina del Hospital de Niños Ricardo Gutiérrez. "El estudio de la vacuna en el que se realizó un seguimiento por 4,5 años demostró una eficacia en prevención de dengue sintomático de 61% y en prevención de hospitalización por dengue de 84%. Son cifras de eficacia muy contundentes" agregó López. Autoridades del Ministerio de Salud de la Nación, en tanto, mantuvieron un encuentro con especialistas y expertos para analizar las diferentes vacunas aprobadas contra el dengue, o en vías de aprobación, así como estudiar las posibles recomendaciones de implementación de una vacuna contra esta enfermedad. De la reunión formaron parte representantes del laboratorio Takeda, como del Instituto Butantan de Brasil y del laboratorio Sanofi-Pasteur, quienes presentaron una actualización de los estudios de fase III de sus vacunas contra dengue. El grupo de expertos y autoridades sanitarias consideraron que, en base a los datos presentados, ninguna vacuna cumple función de bloqueo frente a un brote de dengue como el que tiene lugar actualmente en nuestro país. En ese sentido, coincidieron en que la mejor estrategia de prevención sigue siendo la participación de la comunidad en relación al control y eliminación de criaderos de mosquitos, así como el fortalecimiento de la comunicación de las medidas de prevención para evitar picaduras de mosquitos y el empleo de métodos de aislamiento vectorial (repelentes, espirales, mosquiteros).

Today we will discuss safety, efficacy, and timing of the newer bivalent covid-19 vaccine boosters and how we can fight vaccine fatigue.  Gerard Clancy, MD Senior Associate Dean for External Affairs Professor of Psychiatry and Emergency Medicine University of Iowa Carver College of Medicine Mr. Mike Brownlee, PharmD MS Chief Pharmacy Officer Associate Dean for Clinical Education in the College of Pharmacy UI Health Care Iowa City, IA Patricia Winokur, MD Executive Dean Professor of Internal Medicine University of Iowa Carver College of Medicine Iowa City, IA Financial Disclosures:  Dr. Gerard Clancy, Mr. Mike Brownlee, and the members of the planning committee for Rounding@IOWA have no relevant financial relationships to disclose.  Dr. Pat Winokur has relevant relationships with Pfizer, Inc., Sanofi Pasteur, and Johnson & Johnson. CME Credit Available:  https://uiowa.cloud-cme.com/course/courseoverview?P=0&EID=51795 Accreditation: The University of Iowa Roy J. and Lucille A. Carver College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME Credit Designation: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurses: Effective March 18, 2020, Iowa nurses may use participation in ACCME-accredited education toward their CE requirement for licensure. A certificate of participation will be available after successful completion of the course. (Nurses from other states should confirm with their licensing boards that this activity meets their state's licensing requirements.) Other Health Care Providers: A certificate of completion will be available after successful completion of the course. (It is the responsibility of licensees to determine if this continuing education activity meets the requirements of their professional licensure board.) Date Recorded: 10/21/2022

September 6, 2022 Rockingham County Commissioners MeetingAGENDA1. MEETING CALLED TO ORDER BY CHAIRMAN BERGER2. INVOCATION - PASTOR TORREY EASLER, FIRST BAPTIST CHURCH3. PLEDGE OF ALLEGIANCE4. PROCLAMATION - LANCE METZLER, COUNTY MANAGERROCKINGHAM COUNTY FALL LITTER SWEEP,SEPTEMBER 10 - SEPTEMBER 24, 20225. RECOGNITION - MARK RICHARDSON, COUNTY COMMISSIONERRUSTY GRAY, OUTSTANDING VOLUNTEER6. RECOGNITION - LANCE METZLER, COUNTY MANAGERRESOLUTION CONGRATULATING AND HONORING PINEHALL BRICK, INC.7. APPROVAL OF SEPTEMBER 6, 2022 AGENDA8. CONSENT AGENDA (Consent items as follows will be adopted with a single motion, second and vote, unless a request for removal from the Consent Agenda is heard from a Commissioner)A) Pat Galloway, Finance Director1. Approval - Appropriate $1,175 in donations received for the Hunter Safety Committee. $675 in donations were received in FY 2019-2020,but were not spent. A $500 donation commitment from Duke Energy has recently been received. The committee intends to utilize thesefunds for the upcoming Hunter Safety Day.2. Approval - Appropriate $2,678 of available fund balance in the General Fund for transfer to the 911 Emergency Telephone Special RevenueFund for reimbursement of FY 22 expenses determined to be ineligible for E-911 funds after the State 911 Board review of the annual report.The 911 Board and the State Treasurer office require that this be shown as a transfer of other revenue into the E-911 Fund.3. Approval - Appropriate $84,380 dollars in State Fiscal Recovery Funds awarded to the Rockingham County Library from the State Budget Act of2021 (SL 2021-180).4. Appropriate $10,000 of available fund balance in the General Fund to cover the County cost share of one-half of the cost. These funds will beused to update the Reidsville Industrial Park with flags of the countries represented and refurbish the exit/entrance sign. The City of Reidsvillewill provide the other 50%f of the funding.5. Approval - Increase DSS budget $491,160 for Cardinal Foster Care Sub-Cap revenues that were received in FY 2022 in excess of the FY22 budget. Funds are restricted for future foster care emergency needs and expenditures that are eligible under the fundingagreement.6. Approval - Increase Public Health budget $154,307 for additional State grant awarded for Communicable Disease Pandemic Recovery.B) Rodney Stewart, RCEMS Operations SupervisorApproval - Rockingham County EMS requests the submitted financial statement for Board Approval of accounting reports of billing and collectionsactivity for July 2022 and approve accounts uncollected that are to be written off.C) Todd Hurst, Interim Tax AdministratorApproval - Tax Refunds from August 1, 2022 thru August 23,2022D) A. Lynn Cochran, Senior Planner/Community Development1. Approval - Resolution to appoint Kathleen Patterson as Plat Review Officer for the Town of Mayodan2. Approval- Appointment of Mr. Jeff Kallam of 2828 Harrell Rd., Madison, NC as sitting member of the County Planning Board. Mr. Kallam has resided in the County for more than (5) years.3. Approval - Appointment of Mr. John F. Roberts of 1919 Belmont Rd., Reidsville, NC as an alternate member of the County Planning Board. Mr. Roberts has resided in the County for more than (5) five yearsE) Anthony Crowder, Fire MarshalApproval- Replacement of Monroeton Fire Department's Fire Commissioners, Ellis O'Bryant and Carlyle Butler with the new Fire Commissioners, Jeff Wright and Vernon Link.F) Ben Curtis, Rockingham County Register of DeedsApproval - Resolution Authorizing the Rockingham County Register of Deeds to Temporarily Transfer Records to an Off-Site or Out-of-County Location for Reproduction, Repair or PreservationG) Ronnie Tate, Director of Engineering and Public UtilitiesApproval - Consideration of waiving landfill tipping fee for disposal of debris from the MARC. The majority of the debris is leftover furnishing from the County when they occupied the old Courthouse space. The Museum Board is requesting fee waiver. All material would be removed before October 1, 2022.H) Jason Byrd, District ConservationistApproval - Land considered for Voluntary Agricultural District programI) Trey Wright, Health DirectorApproval - Increase Influenza rates for CPT 90662 Sanofi Pasteur (High Dose - 65+ only) and CPT 90682 Sanofi Pasteur (18 years and older) from $70.00 to $75.00 per CMS Medicare.J) Lance Metzler, County ManagerApproval - Consideration of the Public Property Bus Stop Placement Use AgreementK) John M. Morris - County AttorneyApproval - Consideration of adoption of a Resolution to concur with a request by the North Carolina Department of Transportation, Division of Highways for abandonment of 0.10 miles of SR 1356 (Hawk Road) Madison Township.9. Ronnie Tate, Director of Engineering and Public Utilities Approval - One (1) year service agreement covering operations, maintenance and management at the Landfill. Agreement would be with Wall Recycling.10. PUBLIC COMMENT11. NEW BUSINESS12. COMMISSIONER COMMENTS13. ADJOURN###

  Vidcast:  https://youtu.be/fIsKAx83LyU   Polio is one disease that was eradicated in the United States by an effective vaccination program that continues to this very day.  Yet the poliovirus is back in the New York county of Rockland and is circulating in the water there as well as in population-dense New York City.  Let's look at how we eradicated polio, why this current threat occurred,  and what you need to do to protect yourself from a devastating paralytic disease.   The poliovirus in New York's water and by inference in the gastrointestinal tracts of thousands of New Yorkers is not the wild type that terrorized America up until the mid-20th century.  It is not the wild type that each year paralyzed the extremities and often the respiratory muscles of more than 35,000 Americans and killed thousands, many of whom were children.  It is not the wild type that put Franklin Delano Roosevelt, our 32nd president, in a wheelchair.  And it is not the wild poliovirus that spurred University of Pittsburgh virologist Dr. Jonas Salk to develop the killed-virus vaccine that he and his medical colleagues across our country tested on some 650,000 children in 1954 and that was found to be 80 to 90% effective.  Here is Dr. Salk vaccinating one of my classmates as he did for many of us who participated in the trials at Colfax School in Pittsburgh.   By the way, the Salk vaccine development and the clinical trials that proved it was safe and effective were both paid for by the people of the United States.  They were paid for with 84 million dollars raised by the FDR-founded National Foundation for Infantile Paralysis better known as the March of Dimes and the Mothers' March on Polio.  The polio vaccine was an early example of successful crowd-sourcing. The American people of all ages gave what they could…dollar, dimes, and even pennies.  When Salk refused to patent his vaccine, he added that it belonged to the people and was paid for by the people.  How times have changed!   From this triumph of the 20th century, let's return to the polio challenge of today.  The virus that is now circulating is a vaccine-derived poliovirus or cVDPV for short.  It arose when the inactivated virus used in the Sabin oral polio vaccine that succeeded the injectable Salk killed virus vaccine regained its toxicity in some persons and then spread.  Because of this zombie virus phenomenon, the Sabin vaccine is no longer used in the US, and our children in this country are vaccinated with an inactivated poliovirus vaccine that is the descendant of the Salk Vaccine.   The Sabin vaccine continues to be used in other countries.  The Sabin vaccine-derived poliovirus that popped up in New York is genetically similar to one found in Israel where the man infected with it likely picked it up. This same type of virus has also been detected in the UK.  Poliovirus spreads like wildfire and, as a so-called enterovirus, lives in the gastrointestinal tracts of the infected.  It stays there and can't infect the nervous system of those properly vaccinated against it, and that's where out current problem arises.   The polio vaccination rates in most communities are higher than 90%, but that rate is lower than 80% in some areas including 61% in Rockland County, NY where many parents have an anti-vaccine philosophy.  Without a vaccine-induced immunity, the poliovirus the in the gastrointestinal tract can reach the spinal cord with the paralysis of 1 in every 200 so infected and death in some.    Now that this reactivated poliovirus is circulating in the Northeast, what should you do?  If you were never vaccinated or unsure, you should receive the 3 shot initial series of Salk inactivated vaccine currently produced by Sanofi-Pasteur.  If your vaccination series was incomplete, you should receive an additional booster shot or shots, and this is particularly important for those with weakened immune systems or complicating medical problems such as cancer and heart disease. If you're planning to travel to a country where polio has reappeared or is endemic, you should be boosted,     Don't play around with this virus: it can be devastating and deadly.   https://www.medpagetoday.com/opinion/second-opinions/100223?trw=no https://www.mic.com/articles/102584/the-best-way-to-remember-jonas-salk-polio-pioneer-on-his-100th-birthday     #polio #poliovirus #salk #sabin #cVDPV #vaccination #antivax  

From a kid living on the beaches of Newcastle to running audiobook and podcast company, Audible Europe. Matthew Gain shares his marketing journey from Sydney, all the way to Asia, and how he is now mastering the global environment.  Guest: Matthew Gain is currently the Senior Vice President and Head of Europe Audible, Managing Director Audible GmbH. Before Audible, he developed and led programs for brands such as Samsung, Telstra, KFC, Microsoft, PayPal, Commonwealth Bank, Reckitt Benckiser, News Limited, Sanofi Pasteur among others. Follow him on LinkedIn [https://www.linkedin.com/in/matthewgain/]. Find Us Online: James Lawrence LinkedIn: https://www.linkedin.com/in/jameslawrenceoz/ (https://www.linkedin.com/in/jameslawrenceoz/)  Smarter Marketer Website: https://www.smartermarketer.com.au/ (https://www.smartermarketer.com.au/)  Rocket Agency Website: https://rocketagency.com.au/ (https://rocketagency.com.au/)  Rocket Agency LinkedIn: https://www.linkedin.com/company/rocket-agency-pty-ltd/mycompany/?viewAsMember=true (https://www.linkedin.com/company/rocket-agency-pty-ltd/) Buy Smarter Marketer: Hardcover: https://amzn.to/30O63kg (https://amzn.to/30O63kg)  Kindle: https://amzn.to/2ZqfCWm (https://amzn.to/2ZqfCWm)  About the Podcast: This is the definitive podcast for Australian marketers. Join Rocket Agency Co-Founder and best-selling author, James Lawrence in conversation with marketers, leaders, and thinkers about what it takes to be a smarter and more successful marketer.

CV LA ENTREVISTA 04 DE JULIO 2022, CON: DR. DANIEL GREGORY LOPEZ RODRIGUEZ GERENTE MEDICO DE SANOFI PASTEUR --- Send in a voice message: https://anchor.fm/cv-la-gran-compaia/message

With the pharmaceutical industry becoming more and more heavily competitive, knowing how to conduct an insightful and multidimensional assessment of your Medical Science Liaison (MSL) team to identify gaps and hire the right MSLs to not only accelerate a corporate competitive advantage, but also to cultivate the natural diversity of a proper team for internal peer-to-peer development and external stakeholder rapport is more critical than ever.   With an extensive and influential career in Medical Affairs (MA) at Sanofi Pasteur spanning more than two decades starting in the field and now the current Senior Director of the Field Medical Team in the Vaccines therapeutic unit at Sanofi Pasteur, Christina Tankersley, PharmD has mastered the know-how of building, training, and maturing a diverse, multidisciplinary MSL team. She joins Dr. Peg Crowley-Nowick, Founder and President of Zipher Medical Affairs on this inaugural podcast of the second season of Zipher Medical Affairs Unscripted to share her invaluable experience on how to intentionally identify key diversities needed in constructing a balanced and symbiotic MSL team, and how to overcome the challenges of unifying team members across the now common virtual office settings. Dr. Crowley-Nowick also draws on Dr. Tankersley's vast experience and innate propensity for coaching and mentoring to discuss the possible pitfalls of the industry's current trend in condensing the onboarding experience for MSLs and potentially driving MSLs into the field prematurely and asks her to expound on her innovative approach for onboarding. Lastly, Dr. Tankersley characterizes the fundamental cornerstone of an MSL development plan and fostering actions to support that vision.

Bushra Tahan studied Chemical Engineering and did 2 years of cooperative education (co-op) programs before graduation. She worked for 8 months in the cosmetic manufacturing industry and 4 months in a water treatment plant. She then spent 1 year in a vaccine manufacturing company. She currently is an Engineer-in-Training at Sanofi Pasteur, where she works with Preventative Maintenace Technical Services.

TESTO DELL'ARTICOLO ➜ www.bastabugie.it/it/articoli.php?id=6851L'OMS E' QUASI INTERAMENTE FINANZIATA DALL'INDUSTRIA FARMACEUTICA di Alessandro RimoldiLa maggior parte degli studi, delle ricerche e delle sperimentazioni in ambito sanitario è finanziata dal settore privato, ovvero dall'industria farmaceutica (nel 2019 in Italia il numero di studi clinici indipendenti si è attestato al 23,2%). Scarsi e insufficienti sono i finanziamenti pubblici devoluti a favore della ricerca clinica, con la conseguenza che i ricercatori accademici e gli scienziati che possono permettersi di lavorare senza il sostegno interessato delle case farmaceutiche, costituiscono una piccola minoranza all'interno della comunità scientifica.La "comunità scientifica" perciò, lungi dall'essere quell'ideale di meritocrazia e di confronto alla pari fra scienziati indipendenti che mettono a disposizione il proprio lavoro per il perseguimento del bene comune, è in realtà un luogo ove si perseguono in gran parte gli interessi dell'industria farmaceutica. L'industria farmaceutica controlla, ad ogni livello, ogni settore ed istituzione della sanità.L'Organizzazione Mondiale della Sanità (OMS), l'organismo dell'ONU al vertice della sanità mondiale, contrariamente alla rappresentazione di autorità scientifica imparziale al servizio e tutela della salute dei popoli che ne fanno i principali mezzi di informazione, può essere considerata come un garante di interessi privati. Ed infatti ben 3/4 delle sue risorse finanziarie provengono direttamente o indirettamente dall'industria farmaceutica e dalle aziende produttrici di vaccini.Se formalmente l'OMS è finanziato dai 194 Paesi membri dell'ONU con contributi fissi in base al PIL (congelati dal 1987), nella sostanza sono i contributi volontari (donazioni) di soggetti privati (aziende e fondazioni) la parte più consistente (quasi la totalità) delle entrate finanziarie dell'ente: ovvero 4,6 miliardi di dollari su un budget complessivo di 5,6 miliardi di dollari.A ciò si aggiunga che oltre 4,3 miliardi delle donazioni volontarie sono "legate a un progetto", ossia sono destinate ai progetti specifici decisi dai donatori privati. Così è evidente che aziende farmaceutiche come Sanofi Pasteur e GlaxoSmithKline (che figurano nell'elenco dei principali finanziatori privati dell'OMS) e fondazioni, indirettamente finanziate dalle stesse case farmaceutiche, orientano tramite le proprie "donazioni" le politiche sanitarie dell'OMS a proprio vantaggio e tornaconto.IL MAGGIORE FINANZIATORE DELL'OMS È BILL GATESPeraltro, il maggiore finanziatore dell'OMS è Bill Gates, il quale, attraverso la sua fondazione "Bill & Melinda Gates Foundation" e GAVI Alliance (ente di cooperazione mondiale creato nel 2000 avente come scopo quello di diffondere "l'immunizzazione per tutti" attraverso i vaccini e come principale finanziatore la stessa fondazione "Bill & Melinda Gates"), di fatto controlla l'OMS e ne indirizza la politica, i programmi e le strategie sanitarie. Non si sottraggono a questa logica le agenzie di vigilanza del farmaco, come l'EMA e l'FDA.Per il 2021 il budget annuale dell'EMA, l'Agenzia Europea per i medicinali, ammonta a 385,9 milioni di euro: il 14% dei fondi proviene dall'Unione europea, mentre la restante parte, l'86% delle risorse economiche di cui l'EMA dispone (circa 330 milioni), deriva da tasse e oneri (commissioni) pagate dalle stesse aziende farmaceutiche che desiderano immettere un medicinale sul mercato.È evidente il conflitto di interessi che tale meccanismo di finanziamento crea, posto che il soggetto "controllante" (l'EMA) è direttamente finanziato dal soggetto "controllato" (azienda farmaceutica), e non vi è chi non veda come tale criterio di dipendenza economica sia lo strumento migliore di cui l'industria farmaceutica possa avvalersi per esercitare la sua azione di influenza, di pressione e di controllo sulle decisioni dell'Agenzia.Tale conflitto di interessi mina certamente l'indipendenza e l'imparzialità dell'organismo che si occupa del monitoraggio e dell'approvazione dei medicinali distribuiti negli Stati dell'Unione.La FDA (Food and Drug Administration), la principale Agenzia governativa degli Stati Uniti per il controllo sui farmaci e sugli alimenti, non fa eccezione a questo criterio di finanziamento. Il budget della FDA per l'anno 2019 è stato di 5,9 miliardi di dollari: circa il 55% (3,2 miliardi di dollari), del bilancio è fornito dall'autorizzazione del budget federale, mentre il restante 45%, (2,7 miliardi di dollari), proviene dalle tasse di utenza del settore. Le attività di regolamentazione dei farmaci umani rappresentano il 33% del budget della FDA; mentre il 65% di queste attività è pagato dalle tasse di utenza del settore.Dunque anche sulla più importante agenzia di farmacovigilanza degli Stati Uniti pesano gravi conflitti di interesse, considerato che la quota maggioritaria (65%) delle risorse finanziarie, che la FDA destina per la vigilanza e l'approvazione dei farmaci ad uso umano, proviene da commissioni pagate dall'industria farmaceutica.I CONFLITTI DI INTERESSITralasciando i conflitti di interessi che l'industria farmaceutica ha generato in ambito più particolare, ove la sua azione di ingerenza e influenza si è estesa in modo capillare fino a controllare enti ed istituzioni nazionali, nonché associazioni e società di medici, si evidenzia l'assoluta e grave anomalia che si è venuta a consolidare, a livello globale, negli ultimi decenni nel settore sanitario circa la mancanza di criteri e regole volti ad arginare lo strapotere delle multinazionali farmaceutiche.In giurisprudenza, i principi di imparzialità e indipendenza costituiscono il fondamento giuridico di ogni decisione giudiziaria. L'indipendenza ed imparzialità dell'organo giudicante è sancita: dall'art. 6 della Convenzione Europea dei diritti dell'Uomo; dagli articoli 104 e 111 della Carta Costituzionale; dagli istituti della incompatibilità, astensione e ricusazione previsti dal codice di procedura civile e dal codice di procedura penale (artt. 51 e ss. c.p.c. e artt. 34 e ss. c.p.p.); dagli articoli 8 e 9 del codice etico dei magistrati; dal reato di istigazione alla corruzione previsto dall'art. 322 del Codice Penale che sanziona penalmente l'offerta o la promessa di denaro o qualsiasi altra utilità al pubblico ufficiale. A garanzia e tutela di codesti principi di indipendenza ed imparzialità, l'organo giudicante è finanziato esclusivamente dallo Stato (e per mezzo di esso dalla generalità dei cittadini).In nessuno stato democratico si consentirebbe che un organo giudicante possa accettare denaro, doni o altra utilità da un privato e ancor meno da una delle parti coinvolte nel giudizio. Nessun cittadino tollererebbe di essere giudicato da chi non dà garanzie di assoluta indipendenza e imparzialità. E allora perché il cittadino si dovrebbe affidare ad organismi come l'OMS, l'EMA o l'FDA che prendono decisioni sulla vita e sulla sua salute, allorquando l'attività di tali enti è finanziata, direttamente o indirettamente, dall'industria del farmaco? Perché mai il cittadino si dovrebbe fidare della dichiarazione di pandemia e delle linee guida sanitarie in materia di vaccini assunte e imposte dall'OMS? Perché mai si dovrebbe fidare delle valutazioni e delle decisioni di enti come l'EMA e l'FDA in materia di sicurezza ed efficacia di farmaci e vaccini?L'indipendenza e l'imparzialità dovrebbero valere ancor più in ambito sanitario ove in gioco c'è la vita e la salute dei cittadini. Si deve riflettere sul fatto che fra le tante opzioni di cura del covid-19 (terapie meno costose come il plasma iperimmune, farmaci in uso da anni, ecc.) tali enti abbiano scelto la via della prevenzione sanitaria a mezzo di un "vaccino", se pur sperimentale. Il "vaccino" è un farmaco per tutti, persone fragili e sane, anziani e giovani, e certamente è il più redditizio per le case farmaceutiche, le quali grazie ad esso (e ai richiami periodici già in essere e/o programmati) stanno incrementando a dismisura i propri profitti, mentre i popoli si impoveriscono sempre più per effetto dei lockdown e delle chiusure forzate delle proprie attività.Nel 1976 Henry Gadsen, direttore generale di una delle principali case farmaceutiche al mondo - la Merck - rilasciò la seguente dichiarazione alla rivista "Fortune": «Il nostro sogno è produrre farmaci per le persone sane. Questo ci permetterebbe di vendere a chiunque». Quel sogno (o meglio quell'obiettivo) dell'industria farmaceutica oggi si sta realizzando...

Town Square with Ernie Manouse airs at 3 p.m. CT. Tune in on 88.7FM, listen online or subscribe to the podcast. Join the discussion at 888-486-9677, questions@townsquaretalk.org or @townsquaretalk. With reports that the CDC is narrowing use of the J&J vaccine due to rare odds of a fatal blood-clotting problem called Thrombosis with Thrombocytopenia Syndrome (TTS) occurring (approx.. one case in every 100,000 doses given to women age 30 to 49), many people want to know what the vaccine protocols should be moving forward to those who took J&J. As we take a deeper dive into the CDC announcing new recommendations regarding the Johnson and Johnson vaccine, we also learn that Pfizer has extended their study on vaccinating young children - reporting that the lower-dose version of its vaccine for 2- to 5-year-olds generated a weaker immune response than expected. In this episode, medical experts address questions regarding Omicron, Delta, and the future of COVID-19 vaccinations and vaccines. We also talk with one passionate caller who is very concerned about the physical side effects of the vaccines. Dr. Gregory Poland*: Professor of Medicine & Infectious Diseases, and Distinguished Investigator at the Mayo Clinic Director of the Mayo Clinic's Vaccine Research Group Dr. Michael Chang Pediatric infectious diseases specialist at UTHealth and Children's Memorial Hermann Hospital *Dr. Poland is a paid scientific advisor for Johnson & Johnson/Janssen Global Services LLC. Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co., Medicago, GlaxoSmithKline, Sanofi Pasteur, Emergent Biosolutions, Dynavax, Genentech, Eli Lilly and Company, Kentucky Bioprocessing, Bavarian Nordic, AstraZeneca, Exelixis, Regeneron, Janssen, Vyriad, Moderna, and Genevant Sciences, Inc. Dr. Poland holds patents related to vaccinia, influenza, and measles peptide vaccines. Dr. Poland has received grant funding from ICW Ventures for preclinical studies on a peptide-based COVID-19 vaccine. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies. Town Square with Ernie Manouse is a gathering space for the community to come together and discuss the day's most important and pressing issues. Audio from today's show will be available after 5 p.m. CT. We also offer a free podcast here, on iTunes, and other apps.

In questa puntata parliamo della somministrazione della terza dose di vaccino anti covid-19 (booster), quando e per chi è consigliata, della possibilità di co-somministrazione del vaccino antinfluenzale in sede vaccinale, degli effetti collaterali del vaccino Comirnaty, della necessità di segnalazione degli effetti collaterali sul portale Vigifarmaco ed infine a livello pratico del rilascio del green pass in farmacia.- - - - - - - - -Links:Ema - 4/10/2021 - Comirnaty and Spikevax: EMA recommendations on extra doses and boostersMinistero della Salute (2021) - Parte terza dose ad anziani, RSA e SanitariMinistero della Salute - Piano vacciniAggiornamento vaccini utilizzabili per le dosi "booster" nell'ambito dellaCampagna di vaccinazione anti SARS-CoV-2/COVID-19Adnkronos (5/11/2021) - Vaccino antinfluenzale: co-somministrazione con anti-Covid è sicura ed efficaceComunicato Stampa Sanofi Pasteur - Co-somministrazione vaccino antinfluenzale e vaccino anti-COVID-19: da Sanofi Pasteur il primo studio con i dati positivi a supportoVaxigrip Tetra - Vaccino antinfluenzale 2021-2022, foglietto illustrativoSegnalazione reazioni avverse- - - - - - - - -Per ulteriori informazioni visita il sito web https://www.pillolepodcast.it

In this episode, we speak with Claudia Viloria about her journey from IU Bloomington to Mexico City, where she works as a Public Affairs and Advocacy Manager for Sanofi, a pharmaceutical company dedicated to vaccinations. Claudia has extensive knowledge and wisdom from her five years of experience working in public affairs and non-profits in Mexico, where she has helped build relationships between governmental organizations and Civil Society Organizations starting from her time as a Public Policy Analyst at Centro Eure S.C. to her time with Save the Children Mexico. Claudia tells us all about her career path, the decisions that have influenced her life, and how her time in the College of Arts and Sciences at IU helps her today. Claudia also discusses the importance of overcoming obstacles and moving forward in the face of adversity. Claudia Viloria is a Public Affairs and Advocacy Manager at Sanofi Pasteur in Mexico City. She is a public affairs professional with experiences building relationships across the private, public, and nonprofit sectors. Currently, she promotes and builds alliances with Sanofi, Civil Society Organizations, and other groups in Mexico to promote access to immunizations and health. Claudia graduated from IU in 2016 with Bachelor of Arts degrees in International Studies and Psychology before moving to Mexico and completing her graduate degree in Public Policy Evaluation. Claudia discusses the invaluable transferable skills that stem from her College of Arts and Sciences degrees. We hope you find Claudia's nuggets of wisdom applicable to your current personal and professional lives as she speaks to the importance of remembering that tomorrow is a new day and overcoming obstacles. Enjoy the episode!

Jennifer Grey on family, films and feeling great - Jane's guest today is Jennifer Grey, the iconic actress whose career has spanned more than three decades. Her portrayal of Baby in the beloved classic Dirty Dancing earned her a Golden Globe nomination for best actress. She has also starred in the John Hughes comedy Ferris Bueller's Day Off and in scores of movies and TV shows. Most recently, she appeared in the acclaimed Amazon series Red Oaks, and she is currently teaming up with Lionsgate on their long-awaited sequel to Dirty Dancing, which she will both star in and executive produce. On today's segment, Jennifer talks about her father, the legendary actor, singer and dancer, Joel Grey, and grandfather, the renowned musician and comedian, Mickey Katz. She also discusses her secrets for longevity and resilience, her stress reducers, and her everyday mantras that keep her sane and centered. And just as life is known to imitate art—Jennifer's fictional brother Ferris skipped high school for some much needed me time—Jennifer is also getting her shot at a “me day.” Indeed, she is supporting Flu Shot Fridays. A collaboration between American Nurses Association (ANA) and Sanofi Pasteur, this educational campaign is designed to drive awareness of the importance of flu vaccinations. Listeners will come away feeling Better Than Before on all fronts.

Jennifer Grey on family, films and feeling great - Jane's guest today is Jennifer Grey, the iconic actress whose career has spanned more than three decades. Her portrayal of Baby in the beloved classic Dirty Dancing earned her a Golden Globe nomination for best actress. She has also starred in the John Hughes comedy Ferris Bueller's Day Off and in scores of movies and TV shows. Most recently, she appeared in the acclaimed Amazon series Red Oaks, and she is currently teaming up with Lionsgate on their long-awaited sequel to Dirty Dancing, which she will both star in and executive produce. On today's segment, Jennifer talks about her father, the legendary actor, singer and dancer, Joel Grey, and grandfather, the renowned musician and comedian, Mickey Katz. She also discusses her secrets for longevity and resilience, her stress reducers, and her everyday mantras that keep her sane and centered. And just as life is known to imitate art—Jennifer's fictional brother Ferris skipped high school for some much needed me time—Jennifer is also getting her shot at a “me day.” Indeed, she is supporting Flu Shot Fridays. A collaboration between American Nurses Association (ANA) and Sanofi Pasteur, this educational campaign is designed to drive awareness of the importance of flu vaccinations. Listeners will come away feeling Better Than Before on all fronts.

Host: Michael E. Greenberg, MD, MPH Guest: Randy Young, MD Despite widespread eligibility, only half of Americans received their flu vaccine last year, and only 55% have been fully vaccinated against COVID-19. Dr. Randy Young joins host Dr. Michael Greenberg to discuss the latest coadministration guidelines and how they could impact vaccination rates. This episode is produced in partnership with the American College of CHEST Physicians and sponsored by Sanofi Pasteur.

In this timely episode, we are joined by infectious disease experts Dr. Michael Greenberg of Sanofi Pasteur and Dr. Richard (Rick) Nettles of Johnson & Johnson to discuss respiratory virus immunization.  It touches upon many hot topics, including the inadvertent health consequences of the pandemic. Additionally, they offer fascinating insight into how unprecedented collaboration and transparency have raised the research bar.

Derek Wallace, Vice President and Dengue Global Program Lead at Takeda, discusses the first public presentation of long-term safety and efficacy results from the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial of its dengue vaccine candidate, TAK-003, and the launch of the company's global HCP dengue education platform, Dengue Academy. #Dengue #DengueVaccine Derek Wallace, MBBS, is Vice President and Global Dengue Program Head at Takeda. In this role, Mr. Wallace leads the global program team in the development of Takeda's dengue vaccine candidate (TAK-003). Mr. Wallace joined Takeda in September 2013 as Global Programme Medical Director responsible for the development of TAK-003 as well as Takeda's enterovirus vaccine candidate.Mr. Wallace has over 16 years of experience in clinical development, infectious diseases and medical affairs. Prior to joining Takeda, Mr. Wallace held clinical development and medical affairs positions at Merck, Novartis and Sanofi Pasteur. At Sanofi, Mr. Wallace served as clinical team leader for Sanofi's dengue vaccine candidate, influenza studies and preparations for first-in-human studies of vaccine candidates for malaria and meningitis B. His experience also includes transplant, cardiology and women's health.Mr. Wallace holds a Diploma of Vaccinology from the Institut Pasteur and a Diploma in Pharmaceutical Medicine from University of Wales, Cardiff. He received his Bachelor of Medicine, Bachelor of Surgery from the University of Queensland.

See omnystudio.com/listener for privacy information.

Town Square with Ernie Manouse airs at 3 p.m. CT. Tune in on 88.7FM, listen online or subscribe to the podcast. Join the discussion at 888-486-9677, questions@townsquaretalk.org or @townsquaretalk. COVID-19 vaccines have been out for months and they're now widely available. We discuss some of the new developments in breakthrough infections, fully-vaccinated individuals are infected, vaccines for children ages 12- 15, and concerns over CDC's updated guidelines on masks. Guests are: Dr. Gregory Poland*: Professor of Medicine & Infectious Diseases, and Distinguished Investigator at the Mayo Clinic Director of the Mayo Clinic's Vaccine Research Group Dr. Jill Weatherhead: Assistant Professor in Tropical Medicine and in Infectious Disease at Baylor College of Medicine *Dr. Poland is a paid scientific advisor for Johnson & Johnson/Janssen Global Services LLC. Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co., Medicago, GlaxoSmithKline, Sanofi Pasteur, Emergent Biosolutions, Dynavax, Genentech, Eli Lilly and Company, Kentucky Bioprocessing, Bavarian Nordic, AstraZeneca, Exelixis, Regeneron, Janssen, Vyriad, Moderna, and Genevant Sciences, Inc. Dr. Poland holds patents related to vaccinia, influenza, and measles peptide vaccines. Dr. Poland has received grant funding from ICW Ventures for preclinical studies on a peptide-based COVID-19 vaccine. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies. Town Square with Ernie Manouse is a gathering space for the community to come together and discuss the day's most important and pressing issues. Audio from today's show will be available after 5 p.m. CT. We also offer a free podcast here, on iTunes, and other apps.

Prevenção à doenças, bem-estar, qualidade de vida e vacinas nunca estiveram tão presentes nas conversas das pessoas como agora. Em meio aos desafios da pandemia da Covid-19, Ana Garcia-Cebrian, diretora-geral da Sanofi Pasteur no Brasil, expõe os desafios de comandar a divisão nacional de uma das maiores fabricantes de imunizantes do mundo e aponta como esse período irá transformar a rotina das pessoas e dos líderes de empresas, See omnystudio.com/listener for privacy information.

For tonight's Medical Matters we are joined by Dr Nasiha Soofie, Medical Head at Sanofi Pasteur Vaccines on the myths and misconceptions of Meningitis as a follow up to World Meningitis Day (24 April).  See omnystudio.com/listener for privacy information.

The Weaponization of the CDC Against Public Health Richard Gale and Gary Null Progressive Radio Network, April 30, 2021   What if you were to know that a cabal of corrupt bureaucrats and scientists at the heart of the Centers for Disease Control (CDC) have known for almost two decades that vaccines, including the MMR, can lead to autism and other neurological disorders? Most people are unaware that the CDC is a militarized federal agency further influenced by private pharmaceutical interests. Due to the politicization of national immunization, vaccine efficacy and safety has become all but irrelevant.  Its policies drive profits for itself and its partners. Now the agency is committed to have as many Americans mandated to be fully vaccinated as soon as possible, irrespective of how many lives are destroyed.  The very mindset and disregard for human life that created the notorious Tuskegee experiment is alive and thriving in the innards of the CDC.    It is time to take a hard look at the advocates of compromised pharmaceutical science and the motivations that compel the CDC and it’s vaccine network to systematically mislead the public for personal benefit, power, and greed.  We need to begin to understand that the agency operates as an independent “deep state,” secretive, non-transparent, and conducting itself in covert ways behind the disguise of heralding public health. When the brilliant journalist I.F. Stone wrote, “Every government is run by liars, and nothing they say should be believed,” he may have just as well been speaking about the CDC and its alliance with the pharmaceutical industry, many medical journals, and the mainstream media.   The money-driven institutions of evidence-based medicine and science, which have hijacked America's health agencies--the CDC, FDA, Health and Human Services (HHS), National Institutes of Allergies and Infectious Diseases (NIAID), National Institutes of Mental Health, the National Cancer Institute, and the USDA-- have plunged a stake into the heart of authentic scientific inquiry, knowledge and innovative medical progress.  Its efforts to hermetically seal and silence the debate on vaccination safety with propaganda, coercion, erroneous and deceptive research, and blatant criminality have succeeded in transforming modern vaccinology into an egregious pseudo-science that is today destroying the lives of millions of infants, children and their families.    The deep-seated problems that reside in the CDC are not going unnoticed by a growing number of Americans. A Rand Corporation survey of public trust in the agency during the Covid-19 pandemic found a 10 percent decline. For decades distrust in the CDC has been high among Black Americans; today, levels of trust among non-Hispanic whites and Hispanic respondents are comparable.  One of the fundamental reasons for Americans’ mistrust and skepticism has been the agency’s culture of muddying the lines between scientific facts and compromised opinions that support gross and deep-seated conflicts of interest.     This problem has also entered the ranks of CDC personnel.  A group of CDC scientists who called themselves SPIDER (Scientists Preserving the Integrity, Diligence and Ethics in Research) became anonymous whistleblowers after releasing a written complaint criticizing the agency for operating as a tax-funded subsidiary of the drug industry in partnership with the FDA.  And after a Congressional Government Reform Committee brought CDC officials to testify before legislators, the Committee concluded the agency had routinely allowed scientists with conflicts of interest with pharmaceutical companies to serve on its two advisory committees that make recommendations on vaccine policy   The blurring of the lines between the pharmaceutical industry and our federal health agencies has been a scandal evolving over the course of several decades. The revolving door between private interests and top government employees never ceases to gyrate.  For example, former CDC director Julie Gerberding left government to become president of Merck's vaccine division, a move that has since earned her upwards to $3 million in stock options.  This may seem to be a modest reward for Gerberding heading the agency now irrefutably responsible for the cover-up of the CDC's own studies proving the MMR vaccine increases the risk of autism in African American boys.  The MMR is manufactured by Merck.   Robert Kennedy Jr, one of the nation’s expert watchdogs in the corporatization of our federal medical establishment, has called the CDC "a cesspool of corruption." Unlike the FDA, which has a contract with the American public to assure warnings about health risks and contraindications of registered drugs and medical devices, the CDC has no such contract with the nation's citizenry.  It seemingly holds no ethical standard and abides by no mandated rules of law. For this reason it may be best regarded as an intelligence agency rather than an institution committed to public health.   One recent example of the CDC's covert activities took place in 2016. Across the mainstream media, journalists en masse denounced the documentary film Vaxxed: From Cover-up to Catastrophe. The film recounted the events of CDC whistle-blower Dr. William Thompson and his agency's intentional cover-up and destruction of documents of scientific evidence proving the MMR vaccine caused autism. Rather than denouncing the nation's vaccine agenda, the film uncovers massive corruption in the CDC's vaccine division.  But a problem with the media-wide demonization of the film arose, which included outlets such as ABC, CNN, MSNBC, the Guardian, the Washington Post and the New York Times, Forbes, Rolling Stone and many others. The media blitzkrieg occurred before the film's actual release. None of the journalists had watched it. None knew the underlying story line aside from what could be gleaned from a 3 minute trailer. Our investigative article, "Why is the CDC petrified of the film Vaxxed" uncovered a template for an editorial script upon which all of these reviews were based.  They originated from a single source, and the tracks led to the halls of the CDC. The CDC's partnership and fellowship programs with the Association of Health Care Journalists is nothing less than an intelligence indoctrination program to train journalists to be the mouthpieces of the CDC's fake science. The curriculum held at the CDC's Atlanta campus includes propaganda in federal health policies, epidemiology (no authentic gold standard biological science), pandemic preparedness, vaccine safety and autism. Journalists are also instructed to access CDC publications and databases to peruse federal resources, public relations kits, and propaganda.    Vaccine policy and the development and promotion of the childhood vaccine schedule is only one of the CDC's many corporate tasks. It is not exclusively concerned with the physical and mental health of the nation. It is also engaged in the design and development of biological weapons and threats of bioterrorism. Because vaccines are biological drugs that may be weaponized, they fall under the CDC's purview and jurisdiction. Consequently the Centers work closely with the Department of Defense and the intelligence agencies such as the National Security Agency with whom there is the exchange of data collection and sharing of classified information.  In its April 21, 2000 MMWR report entitled "Biological and Chemical Terrorism: Strategic Plan for Preparedness and Response" the CDC reported that for "the first time the CDC has joined with law enforcement, intelligence and defense agencies in addition to traditional CDC partners to address a national security threat."    This may have been the turning point when the Centers morphed into a pseudo-intelligence agency and assumed a “deep state” role by adopting an inquisitional task of population surveillance and information data collection as a matter of intelligence gathering instead of improving healthcare. During the past years, this has further grown into spying and covert operations against the critics of our national health and immunization policies. Immunization, as described on the CDC's website, is now a matter of national and global security.  Therefore, no longer are vaccines simply a public health intervention. In fact, immunization has been removed from science altogether and consequently can only rely upon flawed and unreliable research to support policy templates and recommendations that get enacted at state levels. These policies are left for politicians to debate, which is rarely done, and is no longer open for discussion among expert medical researchers outside of the CDC’s ranks and its network of trolls, shills and medical puppets spewing disinformation into the public sector.  This alone is sufficient incentive for targeting and silencing voices challenging vaccine safety and efficacy and who demand a reevaluation of vaccination and its toxic ingredients.    Few people realize that the CDC owns 56 vaccine patents; these patents are licensed to drug makers with royalties who later buy and distribute $4.6 billion worth of vaccines through its Vaccines for Children Program, which accounts for 40% of its budget. This has given rise to a 2015 British Medical Journalinvestigative report accusing the CDC of becoming a lapdog for commercial interests.    The CDC also controls a separate non-profit institution known as the CDC Foundation, which operates like an astro turf organization. Founded in 1992 through an amendment inserted into the George H.W. Bush’s Preventative Health Act, the Foundation operates outside of Congressional oversight. This is clearly stated in its documentation:     “The Foundation shall not be an agency or instrumentality of the Federal Government, and officers, employees and members of the board of the Foundation shall not be officers of the Federal government…. The purpose of the Foundation shall be to support and carry out activities for the prevention and control of diseases, disorders, injuries and disabilities, and for promotion of public health… the Foundation shall establish a fund for providing endowments for positions that are associated with the Centers for Disease Control and Prevention…”   In other words, the Foundation has been established as a recruiting service, funded by non-Federal sources, which can include private corporations and drug makers, for the sole purpose to serving the tax-funded CDC.  Moreover, endowments to the Foundation are “unrestricted,” which means they can be spent solely based upon the discretion of the donator and to support the giver’s vested interests.  Among the CDC Foundation’s list of partners we find all of the large vaccine makers – Glaxo, Merck, Novartis, Pfizer, and Sanofi Pasteur – and of course the Bill and Melinda Gates Foundation. A Freedom of Information Act submission discovered that the CDC had been providing guidance to the companies for influencing authorities on sugar and beverage policies. For example, the CDC Foundation receives large donations from Pepsi and Coca Cola, and thereby exerts its influence to taint national guidelines about diabetes, liver disease and other illnesses. In another example, Roche, the manufacturer of the drug Tamiflu against influenza infection, donated $193,000 to the Foundation in return for the CDC’s advocating the drug’s benefits for relieving flu symptoms.  This completely undermines the FDA’s own ruling that Tamiflu’s clinical trial data does not support the claims that the drug saves lives or lessens hospitalization.    It has been through the Foundation that Bill Gates’ faux philanthropy has bought off the CDC. Gates has given tens of millions of dollars to the CDC Foundation over the years.  In 2013, the Bill and Melinda Gates Foundation gave $13.5 million to support the CDC’s efforts to undertake surveillance and increase meningitis and rotavirus vaccination rates in Sub-Sahara Africa.    Furthermore, the Centers' activities are no longer limited to the US' domestic health; after 911, its mission expanded, far beyond its original mandate, and today the agency is globally engaged.  On the Centers’ website, it defines itself as America's "Global Health Protection Agency" in charge of "implementing global health security" and works in partnership with other nations. Since 2006, the CDC claimed it had trained over 115,000 professional personnel in its interpretation of health issues. It’s Global Rapid Response Team of over 400 experts "can deploy in as little as 48 hours" to respond to local and regional health emergencies. In brief, the Centers are immersed in the technology of surveillance, information gathering and analysis. These are among the defining characteristics of an intelligence agency.    Other intelligence activities often associated with a “deep state” and now undertaken by the CDC include pressuring peer-reviewed medical journals to retract studies that challenge their ideology or endanger the agency's reputation.  In 2014, Prof Brian Hooker, a biochemist at Simpson University, reevaluated the CDC's own data showing a 350% increase in autism among African American boys receiving the MMR. Initially approved for publication by the journal Translational Neurodegeneration, the study was shortly thereafter suspended after the CDC pressured the journal with fabricated claims against Dr. Hooker. This is a textbook case of intelligence sabotage of a critic by false accusation.     Similar to the Pentagon and the CIA, the CDC has also infiltrated Hollywood. Hidden within the corridors on the University of Southern California campus is the relatively unknown organization Hollywood Health and Society. Its top funders include the CDC, the National Cancer Institute, the Office of National Drug Control Policy and the largest private funder of vaccines, The Bill and Melinda Gates Foundation.  The small organization's mission is to provide "briefings and consultations with experts, case examples, panel discussions about timely health issues" for Hollywood script writers and producers. Among the main topics listed on its website are influenza, smallpox and autism, all official propaganda stamped with the CDC's seal of approval.    Among the trove of classified national security documents released by NSA whistle-blower Edward Snowden, were several regarding the government's intelligence agencies' infiltration of the internet in order to manipulate information, deceive the public and destroy personal reputations of opponents, including independent journalists.  Among the documents was a manual, "The Art of Deception: Training for Online Covert Operations." One of its stated missions is to flood the internet with false information and data to destroy the reputation of its opponents.  Furthermore, the manual provides instructions on taking control of online public discourse in order to generate allegiance to the intelligence agency's false point of view.    Vaccine opponents often complain about the blogosphere being riddled with anonymous trolls, most who would be unable to debate their way out of cardboard box on scientific issues regarding vaccines, but who nevertheless follow the intelligence manual's strategies to disparage vaccine critics.  Bill Gates, who is on record condemning parents who refuse vaccines and who is no stranger to the higher echelon of executives in the vaccine industry and department heads at the CDC, funded a professor at the University of Connecticut to develop a monitoring system to track all anti-vaccine internet traffic. Given Gate's utter disdain towards voices speaking out against vaccines, we can be certain this was not for humanitarian, research purposes but as part of intelligence gathering in the CDC's war against the health of the nation.  Others who have been CDC mouthpieces yet are viewed as respectable and medically credentialed kingpins, such as Paul Offit, Peter Hotez, Senator Richard Pan, and others are welcomed by the media as the foremost authorities and final voices on vaccine topics.    To our peril, federal agencies take full advantage of the average American's scientific illiteracy.  An important survey conducted by Michigan State University found that only 4% of American adults had an understanding about stem cells. Seventy percent could "not read or understand" the science section in the New York Times.  An earlier study funded by the US National Science Foundation noted that about half of Americans understood that the earth rotates once around the sun annually, 45% of people had an "acceptable" understanding of DNA, and only 22% knew what a molecule was.  Although scientific illiteracy is an enormous threat to a functioning democracy and an informed public, nevertheless it is a boon for the CDC and the vaccine industry. Manipulating this ignorance with heavy doses of fear tactics, such as revealed through the CDC's press model to guide the mainstream media's role in increasing vaccine compliance, health officials have managed to successfully thwart many efforts to educate the public to evaluate the pros and cons of vaccination.    Along with the corporatization of Washington's three branches of government, and the emergence of a surveillance state watching over the shoulders of every citizen, the politicization of medicine, particularly vaccines, is another sign of the further decay of the nation towards totalitarianism. For almost two decades, fake news and bureaucratic deception, anger, hatred and disproportional distrust has taken the spotlight as the nation's health further erodes. Annually, the quality of Americans' health is declining and this is most evident in the younger generations who have received the bulk of vaccines. While the CDC and its allies conjure distorted statistics with no sound scientific basis from thin air in order to convince us that vaccines have saved countless lives, in fact these screeds are no more scientifically reliable than visiting the local gypsy soothsayer to have your palm read. A doctorate in science or a medical degree from Harvard does not excuse a person from duplicitous chicanery.    The good news is that the tide is slowly turning. The populace is steadily losing its faith in government. Autism rates continue to rise and parents are able to access extensive independent medical research to understand the real dangers of vaccines. A fundamental reason why parents increasingly refuse to vaccinate themselves and their children is quite simple; the cartel of pharmaceutical-friendly bureaucrats writing the nation's healthcare policies has been losing the public's trust. There is no secret why federal health officials and their absolutist claims to mandate vaccine compliance are untrustworthy. In 2016 over 1500 medical researchers surveyed by the prestigious journal Nature failed to reproduce another scientist's experimental results. Over half were unable to reproduce their own experiments. The article concludes that the potential reasons for this lack of scientific confirmation are numerous. However, most important is that no single scientific study or paper can claim to be the final word on any medical issue, and this is especially true with vaccine research. The complexities of the human immune system, its biomolecular mechanisms and epigenetic relationships with external environmental factors are not fully understood.  And there remains much more to discover and digest.  Modern immunology still has a long ways to go and needs frequent revision as new discoveries emerge. In contrast, vaccine science continues to rely partially upon an antiquated understanding of the body's immune system focused almost exclusively on antibody generation.   One example of medical negligence has been the rising epidemic of citizens who are immune-compromised and therefore most susceptible to adverse vaccine reactions. When a severe condition of immunosuppression is clearly diagnosed, it is not uncommon for physicians to withhold vaccinations.  But how many Americans are immune-compromised?  When this question was posed to a researcher at Johns Hopkins University in 2015, to his surprise Theo Schall discovered there were no population accurate statistics and none of our federal health agencies nor medical institutions were tracking it.  Not only are these people at higher risk for vaccine injury, they are also at a higher risk for infection from wild viruses. Federal vaccine policies do not differentiate the population with weakened immune systems from healthier individuals. The CDC' immunization schedule is a one-size-fits-all paradigm/ Its bottom line demands that everyone should and must be vaccinated.    After reviewing the different immune-compromised populations (eg, immunosenescence or weakened immunity due to age in the senior population, malnourishment, cancer patients, people with AIDS and HIV, transplant recipients, patients under immunosuppressive drugs with autoimmune conditions, and primary genetic immunodeficiency disorders, Schall estimated there were approximately 122.6 million Americans with a weakened immune system and stand at higher risk for infections. Our revaluation of the available figures places this figure now at 130.4 million, over one-third of the US population.   The question whether 130 million people, including hundreds of thousands of children, should be subject to injections with infectious viruses-- live, attenuated or killed – or now the new generation of mRNA Covid-19 vaccines that have no prior precedence for observing long-term adverse effects, is never discussed. Volumes of medical and biochemical research confirming the severe vaccine ingredients are also ignored. Nor is any consideration given to the number of vaccines administered and the risks due to the accumulative levels of toxic ingredients when multiple vaccines are given simultaneously or within short time intervals. Nor do pediatricians routinely evaluate the state of children's immunological health before determining whether or not to administer vaccines. There is no profit from delaying or postponing vaccination.  No perks are received from insurance companies for increasing vaccination compliance.  And finally, physicians and pediatricians are largely as ignorant as the general public about the scientific evidence supporting and debunking vaccine safety and efficacy myths.  Their primary source of information is channeled through the CDC and its disinformation campaign.    The CDC has yet to conduct or fund definitive and legitimate studies to determine once and for all individual vaccine safety and whether or not vaccines as exogenous factors are contributing to the onslaught of illnesses ravishing the country. Yes, such gold standard studies, which remain absent from the pro-vaccine arsenal, would be very costly.  But that would be the price to pay to bring sanity to the irrational conclusions of the CDC’s decision makers on our nation’s national advisory vaccine committee. Nevertheless, the cumulative financial cost of all previous government sponsored fake science would be a small price to pay for the future well-being of children.     During Congressional proceedings in 2002 into the causes for the unaccountable rise in autism in the United States, CDC officials confirmed no studies have been undertaken to compare the quality of health between vaccinated and unvaccinated children. Yet the subcommittee was assured by the CDC that such studies would be conducted. A decade later, when the CDC was again yanked back into a subcommittee, still no studies had been conducted, and again, Congress was assured such studies were forthcoming.    We should not hold our breath. Officials at the CDC and Department of Health and Human Services know perfectly well that vaccinated children are susceptible to far more allergies and illnesses than their unvaccinated peers.  Their greatest fear is a thorough long-term study to see whether unvaccinated children are indeed healthier. Otherwise, the necessary research to prove the health advantages of vaccines would have been conducted long ago.    Yet there are reasons why such studies are not mandated nor funded. Health agencies are fully aware that vaccines are a scourge. Instead they pump out ecological and epidemiological cohort studies, notorious for subjective manipulation, confounders and biases to support their dogma. Such studies, which are little more than algorithmic equations for sifting, shifting and fudging data, are scientifically invalid for determining any medical truth.  Nevertheless, epidemiological studies remain the most cited articles by the most vocal proponents of vaccination and vaccine mandates.    However, corruption at the CDC is not limited to national vaccine policies and the deceptive manipulation of scientific data to further advance a national vaccination regime. The agency has also been discovered to mislead the nation on other health issues that in turn shape government policies. Earlier it was accused of inflating numbers of rapes in the US. The CDC estimated 2 million rapes occurred within a single year (2011); however, the Justice Department's crime statistics recorded only 238,000. Later Time magazine reported that the manner the CDC gathered its information was extremely flawed and biased.   In 2016 The Hill reported that the CDC misled Congress with its WISEWOMAN project --  a national screening and evaluation project to help reduce heart disease risks in women between 40-64 and to promote healthier lifestyles.  The CDC's data of the project was all "cooked" to make the results look better than it was and that the project was larger and more inclusive than it actually was   The writings of Hannah Arendt over fifty years ago about the origins of totalitarian ideologies and states have never been more poignant and prophetic than today.  She worried deeply about the language of absolutism, and particularly in the realm of science, which is now the underlying mission of the CDC to politicize immunization. The attempt to reduce all of human life to well-defined processes, to predictable patterns and primitive linear reductionism, was in Arendt's view both self-defeating and extremely dangerous for a healthy society. In a totalitarian state, objectivity is tyrannical. Scientific objectivity that threatens the official policy even more so. In the case of vaccines, the entire industry is a creed that has institutionalized a denial of the most fundamental principles of science and fact finding. And worse, the CDC's ongoing war of terror against the unvaccinated has become lawful.  And this is what gives rise to a totalitarian culture of science.    Arendt was certain that a fascist worldview does not necessarily have to be framed in nationalism, religious doctrine nor based upon race and ethnicity. She worried that science, and its technologies, once they become politicized, would give rise to new forms of totalitarianism and persecution in the future. And today this totalitarian stench breathes through many scientific institutions and universities, throughout the private vaccine industry, and its most pungent odor of rot and decay fills the halls of the CDC. 

With all the talk about the COVID vaccine, have we forgotten about other vaccines?  Dr. Ferdaus Hassan, Medical Science Liaison with Sanofi Pasteur joined the Rural Health Voice to discuss meningitis and the need to get vaccinated.  World Meningitis Day is April 24th. VRHA is one of the co-sponsors of the upcoming Appalachian Communities Opioid Response Summit.  Join us online May 19th!  

De nombreux pays ont débuté leur campagne de vaccination contre la Covid-19 depuis plusieurs mois. Où en est la vaccination contre la Covid-19 au niveau mondial, en termes de production et de distribution du vaccin ? L’attention de la communauté internationale est focalisée sur la lutte contre le coronavirus, comment maintenir effective la vaccination contre les autres maladies virales ? Pr Jean-François Saluzzo, consultant vaccin, directeur de production des vaccins, il a travaillé à l’Institut Pasteur de Dakar au Sénégal. Spécialiste de la fièvre jaune. Ancien directeur des vaccins viraux chez Sanofi Pasteur. Auteur de La saga des vaccins contre les virus, aux éditions Belin Retrouvez l'émission en intégralité ici.

It is Time to Dismantle the World Health Organization Richard Gale & Gary Null PhD Progressive Radio Network, April 19, 2021   The ultimate international authority for infectious diseases is the World Health Organization (WHO). Due to its widespread acceptance by the world's national governments, it has been extremely successful in assuming the helm to monitor regional and global infectious diseases and dictate medical intervention policies to international health agencies. The organization has become the final word to rule whether the spread of a serious pathogen is a pandemic or not. For the majority of the medical community, the media and the average person, the WHO is the front line command post for medical prevention (i.e., vaccination) and treatment.  Consequently its rulings are often regarded as the gold standard.  On matters of global health, the WHO holds dominance.  For approximately a year the WHO has propagated the belief that the first line of defense for curtailing the COVID-19 pandemic is self-isolation, distancing, masks and, ultimately, vaccination. Although it approved Ivermectin as a cost-effective treatment against SARS-CoV-2 infections, it disapproved hydroxychloroquine in favor of Gilead Bioscience’s and the National Institute of Allergy and Infectious Disease’s (NIAID) Anthony Fauci’s novel and costly drug Remdesivir.  Much of it’s funding efforts have been reserved for mass-vaccination with the new generation of experimental vaccines. Throughout these efforts, the WHO has allied itself with the US's and UK’s national health systems, and the Bill and Melinda Gates Foundation and his Global Alliance for Vaccines and Immunization (GAVI) initiative.  Most people wrongly assume the WHO acts independently from private commercial and national government interests for the welfare of the world's population. The legitimacy of the WHO as a gold standard of health is dubious. The organization has frequently been accused of conflicts of interests with private pharmaceutical companies and mega-philanthropic organizations such as the Gates’ Foundation, as well as being riddled with political alliances, ideologies, and profiteering motives. Despite it’s mega-pharmaceutical interests and consultants representing private vaccine interests, in the past the WHO has had the audacity to ridicule the pharmaceutical industry of corruption. “Corruption in the pharmaceutical sector occurs throughout all stages of the medicine chain, from research and development to dispensing and promotion…. A lack of transparency and accountability within the medicines chain can also contribute to unethical practices and corruption.” These are similar charges that have been leveled against the WHO. An article in the National Review called the WHO "scandal plagued" with "wasteful spending, utter disregard for transparency, pervasive incompetence, and failure to adhere to even basic democratic standards." In his book, Immunization: How Vaccines Became Controversial, University of Amsterdam professor emeritus Dr. Stuart Blume raises the serious problem of the WHO’s most influential advisors on emergency health conditions, such as the current Covid-19 pandemic and earlier the 2009 H1N1 swine flu scare that never was, serve as consultants for the vaccine industry. During times of global emergencies and crises, the WHO confers with a separate group of advisors outside its formal sitting Strategic Advisory Group of Experts or SAGE; the names of this group’s members are not made public.  We would add that the WHO’s level of incompetence has resulted in serious misinformation about pandemics, medical risks of vaccines and other health-threatening chemicals.  For example, during the early stage of the COVID-19 outbreak in Wuhan, the organization reported it could not find any evidence of human transmission. However, the WHO has repeatedly kowtowed to China’s demands and unscrupulously accepts whatever statistics and statements the Chinese Communist Party (CCP) provides. Responding to a petition signed by over 700,000 signatories demanding the resignation of the current WHO Director General Tedros Adhanom, Japan’s Deputy Prime Minister Taro Aso told the Japanese parliament that the organization “should be renamed the Chinese Health Organization” for favoring China’s policy to stall and obstruct international investigations and for lauding unsubstantiated praise on the country’s transparency and handling of the pandemic. Back on December 31, 2019, Taiwan – which has been barred from WHO membership due to China’s political maneuvering – had been warning of a possible human-to-human transmission contrary to the wet-market narrative, but this was largely ignored in order to avoid upsetting the CCP. The UK’s Sunday Times reported that Chinese scientists were forced to destroy their proof of the virus shortly after its discovery. In the province of Hubei, authorities ordered the cessation of further testing and the destruction of existing samples. Other researchers who made efforts to warn the public were punished.  Writing for The Hill, University of Texas at San Antonio professor Bradley Thayer wrote, “Tedros apparently turned a blind eye to what happened in Wuhan and the rest of China and… has helped play down the severity, prevalence and scope of the Covid-19 outbreak.” Thayer concludes, “Tedros is not fit to lead the WHO.” He has no formal medical training as a physician or any international management experience in global health. Many others have voiced similar criticisms pointing out Tedro’s unsuitable background.  Moreover, the Director General’s conflicts of interest with China abound. Immediately before and after his tenure as the Health Minister for Ethiopia’s ruling Communist party, the Tigray People’s Liberation Front, China had donated an estimated $60 million to the terrorist government and its social programs. Now heading the WHO, Tedros appears to continue lobbying on China’s behalf. In 2017, the Washington Post noted the fundamental problem:  “[China] worked tirelessly behind the scenes to help Tedros defeat the United Kingdom candidate for the WHO job, David Nabarro. Tedros’s victory was also a victory for Beijing, whose leader Xi Jinping has made public his goal of flexing China’s muscle in the world.” Upon assuming his new position at the WHO, Tedros had left Ethiopia’s healthcare system in ruin.  As one young healthcare worker reported, there was no “bare necessities of a health care office…. Sterile gloves, paper exam gowns and covers, cotton swabs, gauze, tongue depressors, alcohol prep pads, chemical test strips, suturing equipment, syringes, stethoscopes… were non-existent. This is a fact in most health care centers in Ethiopia.”  During the more recent re-investigation of SARS-CoV-2 origins, the Chinese authorities refused to provide raw case data and created repressive conditions to curtail reliable analysis and disclosure. The WHO’s final report concluded that the virus had an animal origin and did not escape Wuhan’s high security pathogen laboratory. But there are viable reasons to discredit the report as untrustworthy at best and perhaps intentionally deceptive.  First, the entire agenda of the investigation was staged theater rather than a deep investigation to uncover empirical evidence. The team simply inspected seafood and open-air markets. Consequently, the WHO team returned empty handed and without laboratory records for a proper forensic examination. To call the entire WHO effort gross incompetence would be an understatement. Based upon all the evidence that has emerged, a large number of professional medical voices are calling the entire investigation a farce. Most problematic is the appointment of Peter Daszak on the WHO’s group to carry out the investigation. Daszak, the founding president of the shadowy non-profit organization EcoHealth Alliance, has headed many hunting adventures worldwide to identify the emergence of potential pathogens that could become pandemics. With the intention to divert attention away from an escaped laboratory virus, Daszak stated on a Going Viral podcast there was no evidential reason to visit and inspect the Wuhan laboratory. According to Independent Science News, despite Daszak’s denial of a lab origin, “EcoHealth Alliance funded bat coronavirus research, including virus collection, at the Wuhan Institute of Virology and thus could themselves be directly implicated in the outbreak.” The research at the Wuhan lab included ‘gain of function” efforts on coronaviruses, and received funds directly approved by Anthony Fauci. Newsweek reports the NIH had given a total of $7.4 million to the Chinese lab for the research. The organization has received over $100 million from a variety of sources, including the Department of Defense, Homeland Security, the NIH and undisclosed amounts from the Chinese government. Daszak himself has authored 25 studies funded by the Chinese Academy of Medical Sciences, think tanks, universities, military institutions, and ministries directly connected with the Chinese Communist Party.  Given the halls of power within the WHO, we are outlining some of the more salient reasons why the organization's declarations about infectious diseases, pandemics and vaccination should not be trusted.  Vaccine Promotional Misconduct For many years the WHO's recommendations for certain vaccines were kept secret. Writing in a 2006 issue of the Journal of American Physicians and Surgeons, Dr. Marc Girard uncovered "scientific incompetence, misconduct or even criminal malfeasance" over the intentional inflation of vaccines' benefits while undermining toxicity and adverse effects. Dr. Girard testified as a medical expert for a French court in a criminal trial against the WHO after French health officials obliged the organization to launch its universal Hepatitis B vaccine campaign. The campaign resulted in the deaths of French children. Girard gained access to confidential WHO documents. He noted that the WHO's "French figures about chronic liver diseases were simply extrapolated from the U.S. reports." He further accused the WHO serving "merely as a screen for commercial promotion, in particular via the Viral Hepatitis Prevention Board (VHPB), which was created, sponsored, and infiltrated by the manufacturers." Now during the Covid-19 pandemic, as early as last July, the WHO approved of China’s first vaccine for emergency use, long before it had undergone proper clinical trials and much earlier than Moderna’s and Pfizer’s mRNA vaccines’ approval. Orchestration of Pandemic Panics Before the current COVID-19 pandemic, there was the H1N1 swine flu scare in 2009. However, at the very start the WHO's fear mongering of a global contagion that could exceed the death counts of the 1918 Spanish flu pandemic was solely based on false rhetoric rather than empirical evidence.  The fabrications are believed to have originated from the WHO's senior consultant on viral outbreaks who happens to carry the reputation of being one of the world's leading pandemic alarmists: Dr. Albert Osterhaus, nicknamed "Dr. Flu." At the time, Osterhaus was head of the Department of Virology at Erasmus University in the Netherlands. When the swine flu scare appeared, he was also the president of the European Scientific Working Group on Influenza (ESWI), an organization funded by the major vaccine manufacturers including Baxter, MedImmune, Glaxo, Sanofi Pasteur and others. It was also Osterhaus who transformed an otherwise potentially bad flu season into a global pandemic. The WHO has been criticized harshly in the media for changing the definition of a "pandemic" and in doing so has been charged with benefitting the pharmaceutical industry. The British Medical Journal reported that the WHO failed to report conflicts of interest in its H1N1 advisory group. The journal's Editor-in-Chief Fiona Godlee wrote, "WHO must act now to restore its credibility, and Europe should legislate." The former head of the prestigious Cochrane Database Collaboration’s vaccine studies, Dr. Tom Jefferson, told a Der Spiegel interviewer, “the WHO and public health officials, virologists and the pharmaceutical companies... built this machine around the impending [H1N1] pandemic. And there’s a lot of money involved, and influence and careers, and entire institutions.” When the 2009 H1N1 influenza strain appeared, the WHO rushed forward to mangle its earlier criteria that would realistically define a pandemic. The organization intentionally removed reference to a pathogen’s “severity” as a necessary requirement. “Don’t you think there’s something noteworthy,” Dr. Jefferson continues, “about the fact that the WHO has changed its definition of a pandemic?.... that’s how swine flu has been categorized as a pandemic.” Moreover, the WHO’s decision to label the outbreak as a pandemic was not based upon its own permanent vaccine experts but on the recommendations of a non-disclosed group of outside consultants.  According to a financial forecast published by JP Morgan, the collaboration between the WHO and Osterhaus's ESWI to orchestrate the pandemic would have profited the pharmaceutical industry up to $10 billion. Der Spiegel reported: “The WHO and those in charge of public health, the virologists and the pharmaceutical laboratories....  created a whole system around the imminence of a pandemic. There is a lot of money at stake, as well as networks of influence, careers and whole institutions! And the minute one of the flu viruses mutates we’d see the whole machine roll into action.” In 2010, the EU’s Parliamentary Assembly of the Council of Europe launched an investigation into the evidence that the WHO had created “a fake pandemic” in order to financially benefit the pharmaceutical giants’ vaccine market and to strengthen the influence private drug interests have over the health organization. The Assembly’s chairperson Dr. Wolfgang Wodarg charged the WHO’s fake pandemic as “one of the greatest medical scandals of the century that resulted in “millions being needlessly vaccinated.” Epidemic of Conflict of Interests According to former World Bank geopolitical analyst Peter Koenig, about half of the WHO's budget is derived from private sources -- primarily pharmaceutical companies but also other corporate sectors including the telecommunication and agro-chemical industries. It also receives large donations from large philanthropic organizations such as the Bill and Melinda Gates Foundation and GAVI. Eleven years ago, Gates had committed $10 billion to the WHO; after the US, his Foundation is its second largest donor providing 10 percent of its funding.  His financial commitment aligned with his global ambition to “make this the decade of vaccines.” Koenig also believes that Tedros’s appointment was due to Gates' influence. This may carry some truth because Tedros is a former Chair of GAVI’s Vaccine Alliance. Barbara Loe Fisher at the National Vaccine Information Center estimates that "only about 10 percent of total funding provided by GAVI ($862M) was used to strengthen health systems in developing countries, such as improving sanitation and nutrition, while nearly 80 percent was used to purchase, deliver and promote vaccines."  There is also the deep personal and financial relationship between Gates and the Chinese Communist government that demands further investigation. Gates is a member of the Chinese Academy of Science. For the moment, the WHO has been advising against Covid-19 vaccine passports as a mandate to travel. Nevertheless, China has already launched encrypted digital certificates as proof of vaccination. Given Gates’ close relationship with Chinese officials, perhaps he is awaiting on China to establish a precedent for other nations to agree on a global mandate that will eventually be propagated by the Gate’s network and the World Economic Forum and its Great Reset.  During a 2020 TED talk, Gates had already revealed that digital vaccine passports may be necessary; that part of his speech was edited from the original video, however, Robert Kennedy Jr. tracked down the original footage.  Gates has also 1) commissioned MIT to develop injectable a quantum dot dye system for children, 2) funded MicroChips, a company developing implantable chip-based devices, and 3) purchased 3.7 million shares in Serco who is developing tracing technology to track pandemic infections and vaccine compliance. Finally, Gates shares the Chinese Communist Party’s interests in collecting and ‘mining” citizens’ DNA. A 60 Minutes expose presented the covert activities of BGI Genomics, a CCP-linked firm that has exported Covid-19 tests to “collect, store and exploit biometric information” on American citizens. Independent investigations reveal that the Gates Foundation has collaborated with BGI and it was through Gates’ influence over Obama that the Chinese company entered the US market.  BGI’s RT-PCR kit was promoted by the WHO back in May 2020 for first line emergency diagnostic use. The rationale was that the test was highly sensitive, specific and user-friendly. Subsequently the EU, FDA, and the Australian, Canadian and Japanese health ministries rapidly purchased and deployed it. On its website, the Gates Foundation acknowledges its role in having the PCR tests supplied to the WHO. “Nine Chinese PCR tests were approved by WHO during 2020 under its Emergency Use Listing (EUL) mechanism, with one of the foundation’s partners supplying tests to WHO” Three months later, Sweden filed complaints after reports of a high percentage of false positives from the Chinese tests.  There is in our opinion little doubt that the WHO is another one of Gates' bought off entities for furthering his personal agenda to promote vaccines, genetically modified seeds and chemical agriculture in the developing world.  Vaccine Adverse Effects Monitoring System Needs Overhaul The WHO's Global Advisory Committee on Vaccine Safety is the group responsible for administering vaccine programs in poorer, developing countries. It is also responsible for gathering data on incidents of vaccine injuries. Any deaths following vaccination campaigns are ignored and ruled as coincidental. This policy is based on the erroneous assumption that if no one died during a vaccine's clinical trials, then the vaccine should be regarded as automatically safe and unrelated to any deaths that might occur later. Consequently, the WHO's monitoring system is seriously flawed and requires a major overhaul.  One of the more controversial incidences was the WHO's collaboration with the Bill Gates’ GAVI campaign to launch the Pentavalent vaccine (diphtheria, pertussis, tetanus, HIP and Hepatitis B) in Africa and later in South and Southeast Asia. In India, health officials recorded upwards to 8,190 additional infant deaths annually following Pentavalent campaign.  The WHO’s response was to reclassify its adverse event reporting system to disregard "infant" deaths altogether. Dr. Jacob Puliyel, a member of the Indian government's National Technical Advisory Group on Immunization concluded,  “deaths and other serious adverse events following vaccination in the third world, that use WHO-AEFI classification are not recorded in any database for pharmaco-vigilance. It is as if the deaths of children in low (and middle) income countries are of no consequence.” WHO's Double Standards of Vaccine Safety A more recent scandal erupted during the WHO's Global Vaccine Safety Summit convened in December 2019.  Days before the summit, one of the WHO's medical directors for vaccination, Dr. Soumya Swaminathan, appeared in a public advertisement touting the unquestionable safety of vaccines and ridiculing parents who speak out against vaccination. She assured viewers that the WHO was in control of matters and monitored any potential adverse risks carefully. However, during the Summit, the same Dr. Swaminathan acknowledged vaccine health risks and stated, "We really don't have very good safety monitoring systems." Another Summit participant, Dr. Heidi Larson stated, "We have a very wobbly ‘health professional frontline’ that is starting to question vaccines and the safety of vaccines. When the frontline professionals are starting to question or they don’t feel like they have enough confidence about the safety to stand up to the person asking the questions. I mean most medical school curriculums, even nursing curriculums, I mean in medical school you are lucky if you have half a day on vaccines.” And more noteworthy were the statements by Dr. Martin Howell Friede, Coordinator of the WHO's Initiative for Vaccine Research,  "... I give courses every year on how do you develop vaccines, how do you make vaccines. And the first lesson is while you’re making your vaccine if you can avoid using an adjuvant please do so. Lesson two is if you’re going to use an adjuvant use one that has a history of safety. And lesson three is if you’re not going to do that, think very carefully." In other words, what the WHO presents to the public contradicts what is discussed behind closed doors, another example of the veil of secrecy the organization operates within.  Now we are witnessing more countries halting further administration of AstraZeneca’s Covid vaccine, a vaccine Trump had committed $1.2 billion towards its development. Subsequently the CDC paused Johnson & Johnson’s similar engineered adenovirus vaccine in order to investigate its association with an otherwise rare condition of fatal blood clotting. The WHO on the other hand has ignored these nations’ ethical responsibility to adhere to the precautionary principle. Its own review claimed there were no blood clot links to AstraZeneca’s vaccine; later the WHO changed its tune to “plausible” after EU regulators found a causal link and the New England Journal of Medicine published two studies providing specific details confirming these adverse reactions.  Although acknowledging these risks, the WHO has continued to recommend that mass vaccination proceed as if there were no red alarms.   WHO's Depopulation Efforts with Vaccines Without doubt, the most nefarious activity conducted by the WHO is its alleged support and distribution of vaccines to poorer developing countries that may have been intentionally designed to decrease population rates.  Back in 1989, the WHO sponsored a symposium at its Geneva headquarters on "Antifertility Vaccines and Contraceptive Vaccines." The symposium presented proposals for vaccines that were later discovered to have been laced with the sterilizing hormones HCG and estradiol; the former prevents pregnancy and triggers spontaneous abortions and miscarriages, and the latter can turn men infertile.   In 2015, the Kenyan Conference of Catholic Bishops reported its discovery of a polio vaccine laced with estradiol that was manufactured in India and distributed by the WHO. A year earlier, Dr. Wahome Ngare from the Kenyan Catholic Doctors Association uncovered a tetanus vaccine specifically being administered to women, also distributed by the WHO, that contained the HCG hormone. All of the polio vaccine samples tested contained HCG, estrogen-related compounds, follicle stimulating and luteinizing hormones, which will damage sperm formation in the testes. Even more disturbing, this vaccine was going to be administered to children under five years of age.  However, this is not the first time the WHO appears to have made efforts to use vaccination campaigns for depopulation.  A decade earlier, in 2004, the WHO, UNICIF and CDC launched a vaccination campaign to immunize 74 million African children during a polio outbreak. The initiative encountered a serious obstacle. In Nigeria, laboratory tests on the WHO's vaccine samples resulted in the presence of estrogen and other female hormones. And in the mid-1990s, a tetanus vaccine being administered to Nicaraguan and Filipino girls and women in their child-bearing years was discovered to contain HCG, which accounted for a large number of spontaneous abortions that were reported by Catholic health workers.  Illegal Vaccine Experiments In 2014, The Economic Times of India published a report that provided details of a joint venture between the WHO and the Gates Foundation to test an experimental HPV vaccine on approximately 16,000 tribal girls between the ages of 9 and 15 unwittingly. The experiment was conducted in 2008, and the vaccine is now what we commonly know as Gardasil. Many of the girls, the report states, became ill and some died.  The following year the WHO and Gates Foundation conducted a similar experiment on 14,000 girls with the HPV vaccine Cervarix. Again "scores of teenage girls were hospitalized."  Investigations led by Indian health officials uncovered gross violations in India's laws regarding medical safety. In numerous cases there was no consent and the children had no idea what they were being vaccinated for. The Indian Supreme Court has taken up a case against the duo for criminal charges.  There are many other questionable activities that the WHO has been involved with over the years. However, the above provide sufficient evidence to argue the case that, at least within the upper echelons of the WHO, global health does not stand in high priority.  The organization employs over 7,000 people around the world and most of these have deep concern for improving the lives of populations in poor and developing nations. On the other hand, the WHO's leaders are there largely because the powers of Washington, London and the pharmaceutical industry benefit by the organization advancing its agendas.  Of course, the WHO is not the only health entity with a legacy of corruption.  Corruption appears to be systemic throughout global health and national health agencies.  This topic was featured last year in the prestigious medical journal The Lancet. Author Dr. Patricia Garcia writes,  "Corruption is embedded in health systems. Throughout my life—as a researcher, public health worker, and a Minister of Health—I have been able to see entrenched dishonesty and fraud. But despite being one of the most important barriers to implementing universal health coverage around the world, corruption is rarely openly discussed." Bear in mind, the WHO, along with Bill Gates and his Foundation, and Anthony Fauci at the National Institutes for Allergy and Infectious Disease, are leading the efforts to get the COVID-19 vaccine administered as quickly as possible. Already the Gates Foundation has given $1.75 billion for developing and distributing these vaccines. Do you believe we can trust their judgment and the intense public relations effort that will immediately follow after such a vaccine reaches the market? 

De nombreux pays ont débuté leur campagne de vaccination contre la Covid-19 depuis plusieurs mois. Production, distribution… Comment répondre à cette demande mondiale ? Alors que l’attention de la Communauté internationale est focalisée sur la lutte contre le coronavirus, comment maintenir effective la lutte et la vaccination contre les autres maladies virales ? Pr Jean-François Saluzzo, consultant vaccin, directeur de production des vaccins, il a travaillé à l’Institut Pasteur de Dakar au Sénégal. Spécialiste de la fièvre jaune. Ancien directeur des vaccins viraux chez Sanofi Pasteur. Auteur de La saga des vaccins contre les virus, aux éditions Belin Pr Tandakha Dieye, professeur d’Immunologie à l’Université Cheikh Anta Diop, spécialiste en Vaccinologie et membre de la Commission de vérification de l'élimination de la rougeole et de la rubéole pour l’OMS en Afrique, membre de la Commission consultative de la vaccination «CCVS» ou National Technical Advisory Group «NITAG» du Sénégal Dr Antoine Roux, pneumologue à l’Hôpital Foch à Suresnes, en région parisienne. Cofondateur du site Covidliste, site de mise en relation en temps réel entre les établissements et professionnels de santé qui disposent de doses de vaccins non utilisées, et des volontaires non vaccinés.

Current Affairs programme which provides listeners with the latest local and International news hosted by Elvis Preslin. Tune in 104-107 every Saturday and Sunday morning from 6 to 7 am

Dave Ross, VP of Commercial Operations - North America at Seqirus discusses the recent FDA approval of FLUCELVAX® QUADRIVALENT, Seqirus' cell-based quadrivalent influenza vaccine (QIVc), for an expanded age indication in children two years of age and older. Dave joined Seqirus in October 2017 as Vice President of Commercial Operations – North America. Prior to this, Dave held several senior roles at Sanofi Pasteur, including Head of Marketing and Sales for VaxServe, a subsidiary of Sanofi Pasteur, Head of Strategic Programs for the Global Influenza Franchise, and Head of US Marketing for the Influenza Franchise. He joined Sanofi Pasteur in 2004 from BASF Corporation, where he also held a number of leadership roles in Sales, Marketing, and Finance during his 16-year tenure. Dave has a BS in Finance from Seton Hall University and an MBA from Fairleigh Dickinson University. #Seqirus #QIVc #InfluenzaVaccine

Black Canada Talking™ is a live online event that provides Black Canadians opportunity to give their takes and POVs on stories that are of importance to them. On the March 7, 2021 edition of Black Canada Talking™, the guest was Francis Jeffers. Francis Jeffers is a Graduate of the University of Toronto at Scarborough (1979) with a major in Chemistry and a minor in Political Science. He was employed for 32 years at Sanofi Pasteur in the areas of Quality Control, Production Planning, Materials Management and Purchasing. Mr. Jeffers' extracurricular activities are focused in the promotion of Youth Development/Empowerment, Science/Technology and Engineering within the African-Canadian community and low-income communities. Francis is the Founder/ Curator and Executive Director of the Canadian Multicultural Inventors Museum (CMIM). CMIM is a federally registered non-profit organization/social innovation organization based in Toronto, whose mandate is to educate and increase the public's knowledge, understanding, and appreciation of inventions by individuals from the diverse multicultural communities that make up Canada by collecting, assembling and exhibiting their inventions to the general public through travelling inventions museum. He is the Founder and past Executive Director of The Visions of Science Network for Learning. Visions of Science is an initiative focused on the promotion of Science, Technology and Engineering to the African-Canadian community with a special emphasis on stimulating young people to view the field of Science and Technology as a viable career option. Francis is a member of the Black Scientist's Task Force on Vaccine Equity (BSTFVE). BSTFVE helps people from the Black community get accurate information about the vaccines, provide factual research/studies for Afro/Caribbean audiences, clear up myths and address questions/concerns. During our conversation, Francis talked about: – Some of his family background and getting his passion for science – Leaving Dominica and coming to Toronto – The story behind Visions Of Science (the first Black STEM organization in Canada) which he was part of for twenty-five years – Living in South Africa for three years – The story behind Canadian Multicultural Inventors Museum – The impact of the pandemic on the museum's activities – Being the best time for Africans in the last thousand years You can contact Francis via: Canadian Multicultural Inventors Museum The Visions of Science Network for Learning Email Visit The Dr. Vibe Show™ at www.thedrvibeshow.com Please feel free to email us at dr.vibe@thedrvibeshow.com Please feel free to “Like” the “The Dr. Vibe Show” Facebook Fan Page here God bless, peace, be well and keep the faith, Dr. Vibe 2020 Podcast News Award Winner – Canadian Ethnic Media Association 2018 Innovation Award Winner – Canadian Ethnic Media Association The Dr. Vibe Show™ At “The Good Men Project” One of the first Brand Ambassador's – Cuisine Noir Magazine Dr. Vibe – Producer And Co-host of Black Men Talking On WJMS Radio Dr. Vibe on HuffPost Live – August 2, 2013 2013 Black Weblog Awards Finalist (Best Podcast) 2012 Black Weblog Awards Winner (Best International Blog) 2012 Black Weblog Awards Finalist (Best Podcast) 2011 Black Weblog Awards Finalist (Best International Blog and Best Podcast Series) Black Blog Of The Day – Black Bloggers Network – June 23, 2011 Twitter Twitter hashtag: #DrVibe The Dr. Vibe Show™ – iTunes The Dr. Vibe Show™ – Spotify Dr. Vibe Media – You Tube The Dr. Vibe Show™ – Stitcher Radio The Dr. Vibe Show™ – TuneIn Radio The Dr. Vibe Show™ – Google Play Music The Dr. Vibe Show™ – iHeartRadio The Dr. Vibe Show™ at Anchor Linkedin – The Dr. Vibe Show™ Instagram The Dr. Vibe Show Facebook Fan Page

Ältere Menschen ab 60 Jahren sollen künftig mit einem Hochdosisgrippeimpfstoff jährlich gegen Influenza geimpft werden. Einziger Impfstoff ist Efluelda von Sanofi Pasteur – und wenn dieser nicht lieferbar ist? Im aktuellen PTAheute-Podcast gehen wir dieser Frage nach und klären, ob Senioren leer ausgehen könnten bei den Impfungen.

Numa semana em que a UE enfrentou de frente a escassez de vacinas, noutras regiões do globo a estratégia de vacinação pareceu correr melhor. A negociação da União Europeia terá sido a melhor? Em estúdio estiveram Helena Freitas, diretora-geral da Sanofi Pasteur, Diogo Serra Lopes, Secretário de Estado da Saúde, e por skype entraram o jornalista da SIC em Israel Henrique Cymerman, Paulo Rangel, eurodeputado do PSD, e Céu Mateus, professora de Economia da Saúde na Lancaster University, no Reino Unido. O debate foi moderado por Ricardo Costa e Bernardo Ferrão na noite de 12 de fevereiro na SIC Notícias

Conoce a través del conversatorio entre Sandra Aramburo, Gerente General de Sanofi Pasteur y Alejandro Moreno Salamana, Director General de INALDE Business School, los nuevos retos que trae consigo la implementación de un plan de vacunación, así como los retos directivos que ha traído la pandemia al mundo empresarial.

Dr. Michelle Goveia, MD, Executive Director, Global Medical and Scientific Affairs at Merck Vaccines and Dr. Monica Mercer, MD, Senior Director, Scientific and Medical Affairs at Sanofi Pasteur, discuss new data presented at the IDWeek 2020 virtual meeting on physician and parental attitudes about the use of early-childhood combination vaccines and the potential implications for timely completion of the CDC recommended Child and Adolescent immunization schedule. Michelle Goveia, MD, MPH is an Executive Director in the Global Medical and Scientific Affairs department at Merck Vaccines. She joined Merck in 2002 supporting the clinical development and regulatory interactions for numerous vaccines including rotavirus, hepatitis A, and varicella-containing vaccines. She is currently responsible for leading the efforts to increase global access to Merck’s pediatric and hepatitis vaccines worldwide, which include managing vaccine-related scientific data and recommendations for rotavirus, MMR, varicella, hepatitis A and B, Hib, and a hexavalent combination vaccine. Prior to joining Merck, she was an Epidemic Intelligence Service Officer at the Centers for Disease Control and Prevention, stationed at the California State Health Department. While there she worked with environmental and occupation health issues, including investigation of a new disease among renal patients, was involved in surveillance activities after the World Trade Center events and in the anthrax investigations in New York City and Washington DC. Dr. Goveia received her B.S. Honors degree from the University of Michigan, medical and public health degrees from the George Washington University in Washington, DC and is pediatric board-certified. Her interest in pediatric environmental health has led her to work with the White House and the US Environmental Protection Agency. Monica Mercer, MD is a Senior Director of Scientific and Medical affairs for Sanofi Pasteur. She received her Bachelor’s and Master’s degrees in Microbiology, Pathology and Immunology from the University of Johannesburg, School of Health Sciences, South Africa, and her medical degree from the Faculty of Health Sciences, Wits University School of Medicine. Her post-graduate training included a residency in Family Medicine at the Johannesburg Academic Hospital where she worked as a hospitalist in pediatrics and internal medicine, and conducted trials in infectious diseases, with an emphasis on TB and HIV. Recognizing that healthcare providers (HCPs) lack a fundamental understanding of the field of immunology and its application to clinical practice, Monica with the Immunology department of University of Cape Town have developed an international online educational program “Immunopaedia” for medical students, residents, and HCPs. Monica joined Sanofi Pasteur in 2015 in the department of US Medical Affairs as a regional medical expert for vaccines.

En @NotiPodHoy ✅ Encuesta mundial revela que la experiencia en audio y video serán las habilidades más exigidas para trabajar en los medios en 2021. ✅ WordPress.com lanza curso de podcasting. ✅ Podimo lanza su primera campaña de televisión para fomentar el consumo de podcasts y audiolibros en español. ➽ Tendencias del pódcast de marca B2C para 2021.  ➽ Triton Digital publicó su informe LATAM Podcast Report más reciente.  ➽ M-Audio lanza dos nuevas interfaces de audio para Mac/iOS y PC de un precio bajo.  ➽ Neon Hum Media se asocia con Sony Music Entertainment para hacer crecer la producción de podcasts. 

In this third episode of the three-part series “Influenza and Diabetes,” Drs. John Russell and Neil Skolnik discuss frequently asked questions about diabetes, heart disease, the effects of influenza and the impact of influenza vaccination. They also discuss the details of currently available vaccine choices and strategies to enhance vaccination rates.  This special three-part series is supported by independent educational grant from Sanofi Pasteur. For more information about each of ADA’s science and medical journals, please visit www.diabetesjournals.org. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health

We are currently living in a post-truth era, where embellished information is often presented as true in spirit, and truer than truth itself. The "post-truth era" makes reference to the creation of a discourse that is easy to accept by everyone, and place an emphasis on what will satisfy the emotions and beliefs of the audience, instead of real facts; But how is this phenomenon affecting public health confidence, especially in vaccines and in a time when we need to leverage people's trust the most? To discuss this today is joining us Rafael Pegoraro from Brazil he is a biomedical scientist and vaccines specialist, with a Master degree in vaccinology and immunology with proven experience in Public Health and interventions for vaccination confidence, having worked in the Global Vaccine Public Affairs department at Sanofi Pasteur in Lyon France. Interesting articles: https://www.nature.com/articles/s41567-020-01039-5 https://preprints.scielo.org/index.php/scielo/preprint/view/367

This episode features Ros Hollingsworth. Ros joined Sanofi Pasteur in March 2015. She is currently Global Medical Franchise Head for Influenza, working with her team to develop and execute the global medical strategy for Sanofi Pasteur's licensed influenza vaccines and support pipeline research and development projects, with the recent addition of developmental vaccines for the prevention of COVID-19 disease. Prior to joining Sanofi Pasteur, Ros spent 14 years in Global Medical Affairs at Pfizer with responsibility for pneumococcal conjugate vaccines. She completed her undergraduate, doctoral, and post-doctoral studies at the University of Nottingham in the United Kingdom.

On this episode we are joined by Francisco Roman, PharmD for a discussion on vaccines. There are a lot of conversations around this topic, especially now that influenza season is in full swing and a COVID-19 vaccine is on the horizon. Francisco is a Clinical Pharmacist by training and currently works as a medical science liaison with Sanofi Pasteur vaccines division.Thank you for listening to the Millennial Health Podcast. Please subscribe to the podcast, share with your friends and leave a review on Apple Podcasts. If you have questions or comments feel free to reach out on Instagram and Twitter @DrJaySheree

Quand le vaccin fait défaut, sa nécessité est évidente pour sauver des vies. Quand il est disponible, certains en ont plus peur que de la maladie dont il protège. Or, si la variole a disparu, si on ne meurt plus de varicelle ou de coqueluche, c’est grâce au vaccin. La course actuelle pour trouver un vaccin efficace contre le Covid-19 a-t-elle des précédents ? Quelle est la durée habituelle de recherche et développement pour garantir la sécurité des vaccins ? De quoi les controverses sur les vaccins sont-elles le signe ? Comment expliquer le mouvement Antivax ? Est-ce que la pandémie de Covid-19 peut avoir un impact sur l’opinion publique ? Pr Patrick Zylberman, historien de la santé, professeur émérite à l’École des hautes études en santé publique, ancien membre de la commission des maladies transmissibles du Haut Conseil de la santé publique et cofondateur du Séminaire du Val-de-Grâce sur les maladies infectieuses émergentes. Auteur de l’ouvrage La Guerre des vaccins, aux éditions Odile JacobDr Jean-François Saluzzo, consultant vaccin, directeur de production des vaccins. A travaillé à l’Institut Pasteur à Dakar au Sénégal. Spécialiste de la fièvre jaune. Ancien directeur des vaccins viraux chez Sanofi Pasteur. Auteur de La saga des vaccins contre les virus, aux éditions BelinEmmanuel Bor, responsable pays pour la RDC à Gavi, l’Alliance du Vaccin (partenariat public-privé qui aide à vacciner près de la moitié des enfants du monde contre les maladies infectieuses mortelles et invalidantes).

Vacina é assunto sério, mas não tem sido levado muito a sério. O Brasil tem um programa de imunização reconhecido no mundo todo. Mesmo assim, segundo o Segundo Programa Nacional de Imunizações, tem sido observada uma queda das coberturas vacinais no país desde 2015. Para falar sobre um assunto tão importante, o Media Lab Estadão e a Sanofi Pasteur realizaram o fórum online Estadão Think: Cobertura vacinal e gestão da saúde, para debater a necessidade de conscientizar a população sobre a importância da vacinação para o controle e a erradicação de diversas doenças. Uma vez que a falta de adesão à vacinação pode impactar na saúde da população. See omnystudio.com/listener for privacy information.

Céline Schillinger is a self-described corporate activist, who was called a troublemaker by her bosses. But thanks to her passion to grow and improve on rigid corporate systems, she was awarded Woman of the Year — La Tribune Women's Awards in 2013. Céline was the Head of Quality Innovation & Engagement at Sanofi Pasteur, the vaccines division of the multinational pharmaceutical company Sanofi. Now she is the Founder and CEO of We Need Social.  What Is Covered 03:20 - What does Céline do? 05:35 - Céline's bosses described her as a troublemaker, yet she later went on to become business woman of the year. How did she do it? 09:10 - When Céline felt like she had hit a plateau in her career. 11:30 - You can take 2 paths: You and your co-workers can protest from within the company or you can band together and become constructive. 13:15 - How Céline and her co-workers chose to make their company a better place to work. 16:15 - Céline took 63 proposals into the executive room. 17:55 - Why at the end of that meeting, Céline came out a bit frustrated. 21:05 - When you're trying to make a change in an organization by yourself, there can be a lot of backlash. When you present new solutions in a group setting, organizations by nature have to compromise. 24:35 - People are tired of corporate speak. Customers aren't stupid. 25:55 - Céline says to never stop building trust internally. 27:50 - Right now Céline is heading up the quality control department, working on new and innovative ways to change the way quality is monitored in vaccines. 31:50 - Too often, Céline sees people unhappy at work. When you're unhappy at work, you're probably unhappy at home as well. 33:30 - How does Céline contribute to creating an innovative company culture? 36:35 - Céline talks on how she kept her team accountable and hitting the right metrics. 40:35 - Where is Céline emotionally today? Does she still feel frustrated? 46:05 - What has Céline changed her mind about recently? 48:50 - What does Céline do to remain creative? 50:15 - What does Céline attribute her success to in life? Links and Resources Mentioned in This Episode Connect with Celine Schilinger on LinkedIn https://www.linkedin.com/in/celineschillinger/ We Need Social https://weneedsocial.com/ 

Céline Schillinger is a self-described corporate activist, who was called a troublemaker by her bosses. But thanks to her passion to grow and improve on rigid corporate systems, she was awarded Woman of the Year — La Tribune Women’s Awards in 2013. Céline is now the Head of Quality Innovation & Engagement at Sanofi Pasteur, […]

In the first ever Supply-Side Special, a new periodic interview series by the Supply and Demand Podcast, Mike sits down with John D'Orsi, Drug Product Process Engineer at Sanofi Pasteur - the largest vaccine company in the world and one of the companies currently testing a vaccine for COVID-19. In the episode, John discusses what goes on behind the scenes in the development of a vaccine and how the normally multi-year production of a vaccine is being accelerated to combat COVID-19 safely and effectively. We look forward to producing more Supply-Side Specials in the future!

In this second episode of the three-part series “Influenza and Diabetes,” Drs. John Russell and Neil Skolnik discuss the consequences of influenza for persons with diabetes, the specific benefits of influenza vaccination in persons with diabetes -  including new information on the cardiovascular benefits of influenza vaccination in diabetes -  and discuss the details of currently available vaccine choices.  This special three-part series is supported by independent educational grant from Sanofi Pasteur. For more information about each of ADA’s science and medical journals, please visit www.diabetesjournals.org. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health

Carlos Slim cerca de consolidarse como el rey de las telecomunicaciones en Brasil a punto de comprar Telecomunicaciones Oi. TikTok puede ser prohibido en USA y de ser así también Microsoft podría salvar a esta red social al comprarla y evitar que se pierdan 100 millones de usuarios estadounidenses. Marcelo Ebrard permitió a la empresa francesa Sanofi Pasteur que México forme parte de la Fase III en la lucha para sacar la vacuna contra el Covid-19. Agarraron al supuesto hacker de mas de 130 cuentas de twitter entre ellas, Barack Obama, Jeff Bezos resulto ser un jovencito de tan solo 17 años. Hong Kong retrasa sus elecciones por la pandemia y la oposición se molesta.

Este semana el secretario de Relaciones Exteriores, Marcelo Ebrard, informó que México formará parte del protocolo de pruebas y aprobación de la vacuna contra Covid-19 que desarrolla el laboratorio farmacéutico Sanofi-Pasteur.

This week, Stacey is joined by Holly Baldwin, Quality Validation CSV, Sanofi Pasteur. Stacey and Holly discuss the most important questions when talking about security and data integrity when dealing with third-party suppliers. Top 10 Questions: Can I perform a vendor audit virtually or in-person?What kind of intrusion detection system does SaaS vendor use?Where is the primary and secondary (disaster recovery) data centers? Are either in a co-location site?Where and when is Quality personnel in the validation process? Pre-approval, post-approval, change management?How often does the SaaS vendor audit their offshore resources or third-party companies? What are the consequences if offshore company fails an audit?Does SaaS vendor have documentation on their APIs (Application Programming Interface) , including any existing application assessment results and reports that demonstrate security best practices and audit results?If your company, as Data Controller, needs to notify supervisory authority in 72 hours; what is the timeframe in which SaaS vendor will notify your company?How will you be notified and how long before the implementation of the releases, upgrades and patches is the notification?What is the SaaS vendor’s definition of an emergency change and when is Quality involved?For an unplanned system outage, when will you be notified? How will you be notified? When will you have access to SaaS vendor’s Postmortem and/or CAPA created for unplanned outage?Holly Baldwin has more than two decades in the Life Science Industry, primarily as a Computer System Validation/Quality authority and resource. She is also an expert in 21 CFR Part 11 Assessments, System Development Lifecycle documentation, audit preparedness and System Validation. Holly has been a speaker and trainer, sharing her expertise globally through organizations such as IVT,  ISPE, American Society of Quality, China Medical Device association and for the China  FDA now called the National Medical Products Administration.  More detailed presentation at IVT’s 26th Annual Validation Week October 28-30, 2020 in San Diego2017 Q&A addendum to 21 CFR Part 11 (Clinical Investigations): https://www.fda.gov/files/drugs/published/Use-of-Electronic-Records-and-Electronic-Signatures-in-Clinical-Investigations-Under-21-CFR-Part-11-%E2%80%93.pdfMHRA Rules and Guidance for Pharmaceutical Manufactures and Distributors, EU Guidance on GMP, Section 2, Part 1, subsection 7: Outsourced Activities EU GMP Annex 11, Section 3: Suppliers and Service Providers: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-4/annex11_01-2011_en.pdfFDA Data Integrity and Compliance With Drug cGMP, Dec 2018; http://www.gmp-compliance.org/guidemgr/files/UCM495891.PDFWHO TRS 996, Annex 5; http://www.gmp-compliance.org/guidemgr/files/WHO_TRS_996_ANNEX05.PDFFDA 21 CFR Part 820.50: “Each manufacturer shall evaluate and select potential suppliers, contractors, and consultants on the basis of their ability to meet specified requirements, including quality requirements”GDPR: https://ico.org.uk/for-organisations/guide-to-data-protection/guide-to-the-general-data-protection-regulation-gdpr/  and https://gdpr.eu/data-privacy/ Voices in Validation brings you the best in validation and compliance topics. Voices in Validation is brought to you by IVT Network, your expert source for life science regulatory knowledge. For more information on IVT Network, check out their website at http://ivtnetwork.com.

Yesterday's guest, Bevelyn of Chaz, was arrested again, this time for not wearing a mask, along with Edmee of Manhattan and Ken Scott of the Heavenlies. And Bob Enyart reports the important development that baby body parts are not being used in the $1.6 billion dollar U.S. coronavirus vaccine contract that just went to NOVAX, and that pharmaceutical giant Sanofi Pasteur has now discontinued using fetal tissue in the production of their polio vaccine. Then Bob continues his "train-up your mind" clear thinking segments using the atheist "Euthyphro's Dilemma" argument. Google ranks Bob's Christian reply #1 at kgov.com/euthyphro. Euthyphro Part 1 introduced Socrates' argument. Part 2 evaluated the Divine Command View. Part 3 introduced the Recognition View. In Part 4 the Recognition View Meets the Trinity. Today's Part 5 turns Euthyphro's Dilemma against Bertrand Russell and the atheists. * RSR's HCQ Updates: See rsr.org/hcq for the full list. Most recently, the Int'l Society of Infectious Diseases reports HCQ cut the death rate by half in a Henry Ford Health System study of 2,541 hospitalized patients.* COVID Vaccines: Our friends over at cogforlife.org list the COVID vaccines under development being produced morally including those from Merck, Sanofi, and from NOVAX, which on July 7th received a $1.6 billion dollar U.S. vaccine contract. Those producing vaccines immorally include Moderna and Johnson & Johnson which use fetal tissue. We strongly urge everyone to boycott vaccines developed using tissue harvested from aborted unborn children. (Remember, many institutions and celebrities who have been "pro-choice" all along are now also calling to legalize infanticide, what they call after-birth abortion.) Related: Recently, pharmaceutical giant Sanofi Pasteur discontinued using fetal tissue for its polio vaccine! While many parents have other vaccine concerns this development is an important step toward moral and socially sustainable medicine.* RSR's 25 Christian COVID Conspiracies: Bob presents a list of conspiracies vs. actual pandemic insights.* "Cases Spiking" Fake News through June & July: (July Update) All of the breathless national media reporting on "spikes" in cases through June and July are nothing but fake news when delivered without context. The mainstream media, and even Fox News and many on their network including Neil Cavuto, report "spikes" without putting that data within the needed context of increased testing and especially, the long-term steady reduction in deaths Today's Video Resource: Get out of the Matrix Bob takes on a college professor and her philosophy class in a debate regarding absolutes. Who wins? The students have been taught that nothing is absolutely right or wrong, so Bob asks them if that is absolutely right. And they’ve been taught that they can only know that which their five senses have told them, so Bob asks them which of their five senses told them that. Is the lack of intellectualism in this college class representative of American higher education? You can decide as you view this video, one of Bob’s most extraordinary presentations.

This podcast is one in a series NCSL is producing about states and the coronavirus pandemic. You can find links to podcasts, webinars and other resources at www.ncsl.org/coronavirus Today’s topic could hardly be of greater interest: the hunt for a COVID-19 vaccine. And at the forefront of that effort are the world’s pharmaceutical companies, which are pursuing multiple initiatives to find a vaccine. To discuss that effort is today’s guest,  Clement Lewin, associate vice president for Vaccines R&D Strategy at the pharmaceutical firm Sanofi Pasteur. Lewin, who holds a Ph.D. from the University of London in medical microbiology and has extensive experience in the field of vaccine development, discusses the overall efforts to create a vaccine for COVID-19, and also explain the role state legislators and other policymakers can play in the vaccine process. This podcast was sponsored by Sanofi Pasteur, a member of the NCSL Foundation for State Legislatures. Resources Coronavirus Resources for States Page Coronavirus and State Legislatures in the News Sanofi’s Response in the Fight Against COVID-19 Transcription of OAS Episode 99

In this first episode of the three-part series “Influenza and Diabetes,” Drs. John Russell and Neil Skolnik discuss the epidemiology of influenza, the consequences of influenza for persons with diabetes, and current recommendations for vaccination.  In addition, they discuss issues to think about when organizing our approach to influenza vaccination for this upcoming influenza season.  In episode 2 of this series, Drs. Russell and Skolnik we will look in greater depth at additional consequences of influenza in persons with diabetes. Episode 3 will discuss the different influenza vaccines in detail.   This special three-part series on therapeutic inertia is supported by independent educational grant from Sanofi Pasteur. For more information about each of ADA’s science and medical journals, please visit www.diabetesjournals.org. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health

"LeaderSpeak" Suresh Mahalingam, Independent Director and Member of Audit Committee, Principal Asset Management Private Limited and Former MD & CEO Tata AIA Life Insurance Q&A Annapurna Das, Country Head, Sanofi Pasteur The pharmaceuticals industry has suddenly taken the drivers sear with COVID-19, both financially and in terms of innovation. On one hand, there are high expectations for a vaccine to be developed, and on the other people are bullish about pharma industry in general. Hear from the India Head of Sanofi Pasteur, Ms Annapurna Das and how the future of pharma industry and how they are managing the sudden surge in operations.

Le président Macron est en déplacement dans une usine de Sanofi aujourd’hui, dans le Sud-Est de la France. Pour parler vaccin. Le gouvernement français, comme nombre de ses homologues, est plus que jamais impliqué dans cette quête frénétique du Graal contre le coronavirus. Cette compétition mondiale qui oppose principalement les 5 grands laboratoires (Glaxo GSK, Sanofi Pasteur, Merck, Pfizer, Johnson and Johnson, Astra Zeneca ) capables de mener à bien le processus de la découverte jusqu’à la fabrication d’un vaccin serait devenu un enjeu comparable à la conquête de l’espace dans les années 60. C'est-à-dire une question de nationalisme économique. Pour sécuriser leur approvisionnement, avec si possible des usines sur leur territoire, et aussi pour redorer leur blason souvent terni par leurs errements dans la gestion de la pandémie les gouvernants sortent le carnet de chèque, avec le secret espoir d’être associé au fabricant qui remportera cette course folle. Une centaine de projets sont dans les tuyaux, mais un seul sera pour ainsi dire gagnant, le premier qui sera validé. Car sur le marché des vaccins, il faut être le premier pour rafler la mise. L’Allemagne a fait sensation hier en annonçant une participation de 300 millions d’euros dans le capital de la biotech CurVac Celle que lorgnait Donald Trump pour sa molécule vaccinale prometteuse. CurVac qui a déjà eu un apport de 80 millions d’euros de la Commission européenne va donc bénéficier de larges moyens pour finaliser sa découverte. L’État allemand détiendra environ le quart des actions de cette jeune pousse. L’administration américaine a déjà injecté 2 milliards de dollars dans les laboratoires les plus avancés, dont Sanofi Pasteur ce qui a suscité une belle polémique en France quand son PDG a laissé entendre qu’il servirait d’abord le marché américain. Mais cette polémique est maintenant oubliée. La Chine, elle aussi, soutient à fond ses champions pharmaceutiques en rêvant de réaliser un nouveau numéro de diplomatie sanitaire une fois le vaccin trouvé. La Russie s’est aussi engagée dans cette bataille. Quant à la France, elle multiplie les accords pour s’assurer un accès au produit. Il y a eu le marché passé la semaine dernière avec Astra Zeneca lui garantissant un certain nombre de doses, et il y aura sans doute aujourd’hui une nouvelle annonce avec Sanofi, entreprise dans laquelle l’État a prudemment augmenté sa participation en avril dernier. Les géants de la pharmacie ont-ils vraiment besoin de ces financements publics ? Pour le vaccin, il existe une multitude de coalitions de bailleurs qui financent les recherches des laboratoires. L’apport de l’argent public est un bonus bienvenu, car les investissements sont colossaux et le risque est grand pour l’entreprise. Ce marché est tout petit, il ne pèse que 35 milliards de dollars à mettre en relation avec un marché global de la pharmacie de 1 200 milliards de dollars. Et les retombées demeurent aléatoires. Le vaccin contre la dengue qui devait rapporter un milliard de dollars à Sanofi se vend moins bien que prévu. Pour les grands labos, ce soutien étatique c’est un gage de commandes publiques, et une caution morale si jamais une défaillance de leur vaccin les exposait à des poursuites judiciaires. En contrepartie ils peuvent être soumis à des pressions amicales pour garantir des prix abordables. Dans le cas du coronavirus qui a fait déjà plus de 400 000 morts la chasse au profit parait difficilement soutenable. Ce « nationalisme vaccinal », salutaire ou néfaste pour la recherche ? L’OMS estime que c’est contre-productif. Et on voit en France que le président Macron cherche d’un côté à s’assurer une certaine souveraineté sur la fabrication du vaccin et de l’autre promet une coopération internationale pour partager les bienfaits du vaccin. Dans la réalité, les attentes sont tellement fortes qu’on risque bien d’assister à une bataille comparable à celle des masques une fois qu’un vaccin sortira. Car la production à grande échelle d'un produit réclamé au même moment dans le monde entier est une prouesse industrielle, on évoque déjà les pénuries de flacon ou de seringue, sans parler de la disponibilité des usines nécessaires à la fabrication de la molécule. Il faut aussi raison garder rappellent les chercheurs : la découverte du vaccin n’est pas automatique, on attend toujours celui qui nous immunisera contre le sida ou l’hépatite C.

Ms. Debi Vinnedge returns to the St. Philip Institute Podcast to discuss some good news for the pro-life cause! Join Debi, Bishop Strickland, and Stacy as they discuss the significance of the latest news from Sanofi Pasteur - a pharmaceutical giant which has just discontinued the development of a vaccine made from aborted fetal tissue.

Why the World Health Organization Deserves Our Distrust Richard Gale & Gary Null PhD Progressive Radio Network, May 8, 2020   Many more questions are being raised than there are answers being discovered concerning the recent strains of coronavirus. Where and how did it originate? Was it the result of human engineering and manipulation or is it a strain that mutated naturally?  What are the best tests to determine exposure and infection? Why are so many infected individuals asymptomatic? Are all elderly people equally susceptible to infection and how much do co-morbidities determine outcomes? These are just several of the important questions that still require definitive answers. The ultimate international authority for infectious diseases is the World Health Organization (WHO). Because of its acceptance by the world's national governments, it has been extremely successful in its mission. The WHO is the final word in determining whether the spread of a serious pathogen is ruled as a pandemic or not. For the majority of the medical community, the media and the average person, the WHO is the front line command post for medical prevention (i.e., vaccination) and treatment.  Consequently it's rulings are often regarded as the gold standard by which many nations design their health policies and intervening protocols to protect their citizens.  On matters of global health, the WHO holds dominance. We are currently being told by the Director General of the WHO that the solutions for curtailing the COVID-19 pandemic are self-isolation, distancing, masks, and, for those in acute stages of infection, ventilation. To date there is no drug that has been found to be universally safe and effective. Therefore, all efforts, with massive funding, are being devoted to rapidly get a coronavirus vaccine on the market.  And in this effort, the WHO is a close ally and advocate in the US's federal health system, notably the CDC and the National Institute of Allergy and Infectious Diseases (NIAID) headed by Dr. Anthony Fauci. Most people assume the WHO acts independently from private commercial and national government interests for the welfare of the world's population. However, at best this is an assumption. Moreover, the very legitimacy of the WHO as a gold standard of health is questionable. The organization has been accused of conflicts of interests with private pharmaceutical companies and mega-philanthropic organizations such as the Bill and Melinda Gates Foundation, as well as being riddled with political alliances, ideologies, and profiteering motives.  An article in the National Review called the WHO "scandal plagued" with "wasteful spending, utter disregard for transparency, pervasive incompetence, and failure to adhere to even basic democratic standards." We would also add that its level of incompetence has resulted in serious misinformation about the medical risks of vaccines and other health-threatening chemicals.  For example, during the early stage of the COVID-19 outbreak in China, the organization reported it could not find any evidence of human transmission. Now we know it is perhaps the most transmittable respiratory viral infection encountered in modern medical history. Given the halls of power within the WHO, we are outlining some of the more salient reasons why the organization's declarations about infectious diseases, pandemics and vaccination should not entirely be trusted. Vaccine Promotional Misconduct Very few will know that for a long time, the WHO's recommendations for certain vaccines were kept secret. Writing in a 2006 issue of the Journal of American Physicians and Surgeons, Dr. Marc Girard uncovered "scientific incompetence, misconduct or even criminal malfeasance" over the intentional inflation of vaccines' benefits while undermining toxicity and adverse effects. Dr. Girard was called upon as a medical expert by the French courts in a criminal trial against the WHO after French health officials obliged the organization to launch its universal Hepatitis B vaccine campaign. The campaign resulted in the deaths of French children.  Consequently, Girard gained access to confidential WHO documents. He notes that the WHO's "French figures about chronic liver diseases were simply extrapolated from the U.S. reports." He further accused the WHO serving "merely as a screen for commercial promotion, in particular via the Viral Hepatitis Prevention Board (VHPB), which was created, sponsored, and infiltrated by the manufacturers." Orchestration of Pandemic Panics Before the current COVID-19 pandemic, there was the H1N1 swine flu scare in 2009 that came and went as a church mouse. However, at the very start the WHO's fear mongering of a global contagion that could exceed the death counts of the 1918 Spanish flu pandemic was based on false assumptions.  The fabrications are believed to have originated from the WHO's senior consultant on viral outbreaks who happens to be one of the world's leading pandemic alarmists: Dr. Albert Osterhaus who carries the nickname "Dr. Flu." Osterhaus is head of the Department of Virology at Erasmus University in the Netherlands. At the time of the H1N1 pandemic, he was the president of the European Scientific Working Group on Influenza (ESWI), an organization funded by the major vaccine manufacturers including Baxter, MedImmune, Glaxo, Sanofi Pasteur and others. It is ESWI's agenda to vaccinate the entire world against the swine flu. It was also Osterhaus who transformed an otherwise potentially bad flu season into a global pandemic. The WHO has been criticized harshly in the media for changing the definition of a "pandemic" and in doing so has been charged with benefitting the pharmaceutical industry. Moreover, the British Medical Journal reported that the WHO failed to report conflicts of interest in its H1N1 advisory group. The journal's Editor-in-Chief Fiona Godlee wrote, "WHO must act now to restore its credibility, and Europe should legislate." According to a financial forecast published by JP Morgan, the collaboration between the WHO and Osterhaus's ESWI to orchestrate the pandemic would have profited the pharmaceutical industry up to $10 billion. The popular German magazine Der Spiegel reported: “The WHO and those in charge of public health, the virologists and the pharmaceutical laboratories....  created a whole system around the imminence of a pandemic. There is a lot of money at stake, as well as networks of influence, careers and whole institutions! And the minute one of the flu viruses mutates we'd see the whole machine roll into action.” Epidemic of Conflict of Interests According to former World Bank geopolitical analyst Peter Koenig, about half of the WHO's budget is derived from private sources -- primarily pharmaceutical companies but also other corporate sectors including the telecommunication and agro-chemical industries. It also receives large donations from large philanthropic organizations such as the Bill and Melinda Gates Foundation. It is believed, according to Koenig, that the appointment of the WHO's current Director General, Dr. Tedro Adhanom, was due to Gates' influence. Tedros is the former Chairman of Gates funded GAVI Vaccine Alliance. GAVI's sole mission is to vaccinate every child in the world. The WHO and the US and British governments are the primary partners and the largest funder is the Bill and Melinda Gates Foundation. There is in our opinion little doubt that the WHO is another one of Gates' bought off entities for furthering his personal agenda to promote vaccines, genetically modified seeds and chemical agriculture in the developing world. Barbara Loe Fisher at the National Vaccine Information Center estimates that "only about 10 percent of total funding provided by Gavi ($862M) was used to strengthen health systems in developing countries, such as improving sanitation and nutrition, while nearly 80 percent was used to purchase, deliver and promote vaccines." The WHO as America's Poodle According to the Kaiser Family Foundation's fact sheet for the US government and WHO, the US is the largest contributor to the global organization. The CDC also provides its technical support and has liaisons at the WHO's Geneva headquarters and regional offices. In summary, there is a strong rationale to suggest that the WHO, aside from its global health programs in other countries, is largely doing the bidding of the US government to advance corporate interests and American neoliberal hegemony. Vaccine Adverse Effects Monitoring System Needs Overhaul The WHO's Global Advisory Committee on Vaccine Safety is the group responsible for administering vaccine programs in poorer, developing countries. It is also responsible for gathering data on incidents of vaccine injuries. Any deaths following vaccination campaigns are ignored and ruled as coincidental. This policy is based on the erroneous assumption that if no one died during a vaccine's clinical trials, then the vaccine should be regarded as automatically safe and unrelated to any deaths that might occur. Consequently, the WHO's monitoring system is seriously flawed and requires a major overhaul. One of the more controversial incidences is the WHO's collaboration with the Bill Gates funded GAVI Vaccine Alliance campaign to launch the pentavalent vaccine (diphtheria, pertussis, tetanus, HIP and Hepatitis B)  in Africa and later in South and Southeast Asia. In India, health officials recorded upwards to 8,190 additional infant deaths annually following pentavalent vaccination.  The WHO response was to reclassify its adverse event reporting system to disregard "infant" deaths altogether. Dr. Jacob Puliyel, a member of the Indian government's National Technical Advisory Group on Immunization concluded, “deaths and other serious adverse events following vaccination in the third world, that use WHO-AEFI classification are not recorded in any database for pharmacovigilance. It is as if the deaths of children in low (and middle) income countries are of no consequence.” The WHO's Director General's Troubled Past Given the enormous number of experts in infectious disease and control, it is astounding that the WHO's current Director General is Dr. Tedros Adhanom Gebreyesus. He was a leading politician in the militant communist Tigray People's Liberation Front that ruled Ethiopia between 1991 to 2018.  Tedros served dual roles as the country's Health and Foreign Minister. According to the British journalist Thomas Mountain, who has lived in neighboring Eritrea for many years and has reported on the corrupt Tigray regime, Tedros had a direct role in the atrocities alleged to have been committed by the government.  It was Tedros who has been reported to have been responsible for the removal of the Red Cross and Doctors Without Borders following Ethiopia's brutal massacre of Ogaden citizens in Somalia, which was immediately followed by a cholera outbreak. As noted above, his approval to head of the organization may likely have been vetted by Bill Gates. Looking back at his past three years at the WHO, Mountain remarks, "For almost three years he remained quiet about the almost total lack of preparation at the WHO for what numerous panels had warned was inevitable, a highly contagious and deadly virus quickly spreading across the world." WHO's Depopulation Efforts with Vaccines Without doubt, the most nefarious activity conducted by the WHO is its alleged support and distribution of vaccines to poorer developing countries that may have been intentionally designed to decrease population rates.  Back in 1989, the WHO sponsored a symposium at its Geneva headquarters on "Antifertility Vaccines and Contraceptive Vaccines." The symposium presented proposals for vaccines that were later discovered to have been laced with the sterilizing hormones HCG and estradiol; the former prevents pregnancy and triggers spontaneous abortions and miscarriages, and the latter can turn men infertile.  In 2015, the Kenyan Conference of Catholic Bishops reported its discovery of a polio vaccine laced with estradiol that was manufactured in India and distributed by the WHO. A year earlier, Dr. Wahome Ngare from the Kenyan Catholic Doctors Association uncovered a tetanus vaccine specifically being administered to women, also distributed by the WHO, that contained the HCG hormone. All of the polio vaccine samples tested contained HCG, estrogen-related compounds, follicle stimulating and luteinizing hormones, which will damage sperm formation in the testes. Even more disturbing, this vaccine was going to be administered to children under five years of age. However, this is not the first time the WHO appears to have made efforts to use vaccination campaigns for depopulation.  A decade earlier, in 2004, the WHO, UNICIF and CDC launched a vaccination campaign to immunize 74 million African children during a polio outbreak. The initiative encountered a serious obstacle. In Nigeria, laboratory tests on the WHO's vaccine samples resulted in the presence of estrogen and other female hormones. And in the mid-1990s, a tetanus vaccine being administered to Nicaraguan and Filipino girls and women in their child-bearing years was discovered to contain HCG, which accounted for a large number of spontaneous abortions that were reported by Catholic health workers. Illegal Vaccine Experiments In 2014, The Economic Times of India published a report that provided details of a joint venture between the WHO and the Gates Foundation to test an experimental HPV vaccine on approximately 16,000 tribal girls between the ages of 9 and 15 unwittingly. The experiment was conducted in 2008, and the vaccine is now what we commonly know as Gardasil. Many of the girls, the report states, became ill and some died. The following year the WHO and Gates Foundation conducted a similar experiment on 14,000 girls with the HPV vaccine Cervarix. Again "scores of teenage girls were hospitalized."  Investigations led by Indian health officials uncovered gross violations in India's laws regarding medical safety. In numerous cases there was no consent and the children had no idea what they were being vaccinated for. The Indian Supreme Court has taken up a case against the duo for criminal charges. WHO's Double Standards of Vaccine Safety A more recent scandal erupted during the WHO's Global Vaccine Safety Summit convened in December 2019.  Days before the summit, one of the WHO's medical directors for vaccination, Dr. Soumya Swaminathan, appeared in a public advertisement touting the unquestionable safety of vaccines and ridiculing parents who speak out against vaccination. She assured viewers that the WHO was in control of matters and monitored any potential adverse risks carefully. However, during the Summit, the same Dr. Swaminathan acknowledged vaccine health risks and stated, "We really don't have very good safety monitoring systems." Another Summit participant, Dr. Heidi Larson stated, "We have a very wobbly ‘health professional frontline' that is starting to question vaccines and the safety of vaccines. When the frontline professionals are starting to question or they don't feel like they have enough confidence about the safety to stand up to the person asking the questions. I mean most medical school curriculums, even nursing curriculums, I mean in medical school you are lucky if you have half a day on vaccines.” And more noteworthy were the statements by Dr. Martin Howell Friede, Coordinator of the WHO's Initiative for Vaccine Research, "... I give courses every year on how do you develop vaccines, how do you make vaccines. And the first lesson is while you're making your vaccine if you can avoid using an adjuvant please do so. Lesson two is if you're going to use an adjuvant use one that has a history of safety. And lesson three is if you're not going to do that, think very carefully." In other words, what the WHO presents to the public contradicts what is discussed behind closed doors, another example of the veil of secrecy the organization operates within. Suppression of the Dangers of Depleted Uranium The use of depleted uranium pervades military missiles and bombs. Tons of depleted uranium were deployed during the US invasions of Afghanistan and Iraq.  It is estimated that the US fired over 300,000 rounds of depleted uranium, or 1,000 tons, during the 2003 Iraq war. In both countries, the WHO has been very active in providing health needs to the populations affected.  However, in regions where bombing was most intense, such as in Fallujah Iraq, there has been a high prevalence of congenital birth defects. This was uncovered by an on-the-ground investigation conducted by the Brussels Tribunal.  According to a BBC documentary, there is no longer any doubt about depleted uranium's association with genetic damage and birth defects.  According to an article published in the British Medical Journal in 2013, the WHO intentionally suppressed the scientific evidence .  The question remains why?  Hans von Sponeck, a former Assistant Secretary General for the United Nations has suggested that "the US government sought to prevent WHO from surveying areas in southern Iraq where DU has been used and caused serious health and environmental dangers."  Here we find a likely case of the WHO doing the bidding of the US government and its military adventures in regime change. There are many other questionable activities that the WHO has been involved with over the years. However, the above provide sufficient evidence to argue the case that, at least within the upper echelons of the WHO, global health does not stand in high priority.  The organization employs over 7,000 people around the world and most of these have deep concern for improving the lives of populations in poor and developing nations. On the other hand, the WHO's leaders are there largely because the powers of Washington, London and the pharmaceutical industry benefit by the organization advancing its agendas. Of course, the WHO is not the only health entity with a legacy of corruption.  Corruption appears to be systemic throughout global health and national health agencies.  This topic was featured last year in the prestigious medical journal The Lancet. Author Dr. Patricia Garcia writes, "Corruption is embedded in health systems. Throughout my life—as a researcher, public health worker, and a Minister of Health—I have been able to see entrenched dishonesty and fraud. But despite being one of the most important barriers to implementing universal health coverage around the world, corruption is rarely openly discussed." Bear in mind, the WHO, along with Bill Gates and his Foundation, and Anthony Fauci at the National Institutes for Allergy and Infectious Disease, are leading the efforts to develop a COVID-19 vaccine. Do you believe we can trust their judgment and the intense public relations effort that will immediately follow after such a vaccine reaches the market?  

Comprendre la crise sanitaire, sociale, économique, marketing et son impact pour la société d'après confinement est l'objectif de cette série de webinars. Chacun sera animé par les experts des différentes entités du groupe Ifop pour vous apporter des éclairages, des points de vue solides, loin des prédictions souvent peu fondées auxquelles nous sommes trop souvent soumis en ce moment. Appuyées par des données exclusives et par nos réflexions, ainsi sur que des témoignages extérieurs, ils vous aideront à comprendre en quoi cette période est un labo mais aussi une loupe grossissante des questions clés posées par notre société aujourd'hui et demain. Pour mieux l'appréhender et mieux anticiper l'après. Nous vous invitons avec cette nouvelle émission à décrypter les enjeux que l'écosystème de la santé aura à résoudre pour gérer la crise d'après confinement et d'après-demain. Ce webinar vous livrera le point de vue de deux experts du pôle Ifop Healthcare, ainsi que l'avis  d'un expert d'un grand groupe pharmaceutique, Sanofi Pasteur, avec lequel Ifop Healthcare travaille régulièrement.  Christina Bienenfeld, Directrice du pôle Ifop Healthcare, et William MacGillivray, Directeur de clientèle du Pôle Ifop Healthcare apporteront un éclairage sur la  prévalence du Covid-19 dans la population française,  les conséquences de cette pandémie sur la continuité des autres soins, et sur la relation aux médecins, Bruno Donini, Directeur des Affaires Publiques chez Sanofi Pasteur, abordera les enjeux liés au développement d'un futur vaccin contre le SRAS Cov2 : les pistes de recherche, mais aussi les défis liés à la production, la distribution jusqu'à l'acceptation de ce nouveau vaccin dans la population. Plus largement, il abordera l'engagement fort de Sanofi dans la lutte contre la pandémie.Veuillez trouver ci-dessous le support de présentation en téléchargement en cliquant ici.

Ira Pastor, ideaXme life sciences ambassador, interviews Dr. Stanley Plotkin, Professor Emeritus at both Wistar Institute and the University of Pennsylvania and consultant to the vaccine industry. Ira Pastor Comments: So as we sit here a few months into the global Covid-19 pandemic, one big question on everyone’s mind is when will we see the first mass produced vaccine against this current strain, especially as it looks like in the United States there will be some loosening of quarantine / "shelter in place" rules to re-start the economy. Dr. Stanley Plotkin: Dr. Stanley Plotkin is an American physician, scientist, and scholar, in many circles referred to as “the Godfather of Vaccines", who in the 1960s, while working at Wistar Institute in Philadelphia, played a pivotal role in discovery of a vaccine against Rubella virus (also known as German measles or three-day measles), which is now used worldwide (as a key component of the MMR vaccine - a combination vaccine also that protects against measles and mumps) and has worked extensively on the development and application of a wide range of other vaccines including polio, rabies, varicella, rotavirus and cytomegalovirus. Dr. Plotkin graduated from New York University in 1952 and obtained a medical degree at Downstate Medical Center in Brooklyn. He was a resident in pediatrics at the Children’s Hospital of Philadelphia and at the Hospital for Sick Children in London. In 1957, Dr. Plotkin served in the Epidemic Intelligence Service of the Centers for Disease Control (CDC) of the U.S. Public Health Service for three years, and then served as a member of Wistar’s active research faculty from 1960 to 1991. Today, in addition to his emeritus appointment at Wistar, he is also Professor Emeritus of Pediatrics at the University of Pennsylvania, and works as a consultant to vaccine manufacturers, such as Sanofi Pasteur, as well as biotechnology firms, non-profits and governments. Dr. Plotkin's book, "Vaccines", remains the standard reference on the subject. Dr. Plotkin is also an editor with Clinical and Vaccine Immunology, which is published by the American Society for Microbiology in Washington, D.C. On this episode we will hear from Dr. Plotkin: About his background; how he became interested in medicine, research, and how after joining Wistar (under the equally famous Dr. Hilary Koprowski), and working for a bit with Anthrax, how Rubella became a target of interest, His thoughts on Covid-19: how worried / concerned / optimistic he is about vaccine development. How with dozens of coronavirus vaccine candidates being developed, in various companies and organizations (including RNA vaccines, DNA vaccines, single protein vaccines, multiple protein vaccines, etc.) how a choice is made of which "to go with" once some are approved. About the requirement for a "perfect vaccine" with 100% coverage, versus less perfect vaccines that could get to market earlier. The topics of Plant BioTechnology, edible vaccines and the Anti-Vaccine movement. Credits: Ira Pastor interview video, text, and audio. Follow Ira Pastor on Twitter:@IraSamuelPastor If you liked this interview, be sure to check out ourinterview with Dr. Linfa Wang: Hunting Down Covid-19 and Other Deadly Diseases! Follow ideaXme on Twitter:@ideaxm On Instagram:@ideaxme Find ideaXme across the internet including on iTunes,SoundCloud,Radio Public, YouTube, TuneIn Radio,I Heart Radio, Google Podcasts, Spotify and more. ideaXme is a global podcast, creator series and mentor programme. Our mission: Move the human story forward!™ ideaXme Ltd.

Na wspólnej konferencji premier Mateusz Morawiecki, minister zdrowia Łukasz Szumowski i minister edukacji Dariusz Piontkowski ogłosili, że zajęcia w szkołach najwcześniej rozpoczną się po świętach wielkanocnych. I co ważniejsze ogłosili, że wprowadzają w Polsce stan epidemii, który pozwala na surowsze ograniczeń i kontrole, na przykład władze będą mogły zamknąć miasta i zakazać wjazdu czy wyjazdu z różnych obszarów. Wprowadzenie stanu epidemii nie oznacza przesunięcia terminu wyborów prezydenckich. Słyszymy o kolejnych politykach, którzy są zarażeni koronawirusem i objęci kwarantanną domową. Dziś dowiedzieliśmy się o pozytywnych wynikach testów jednego z wiceministrów w resorcie zdrowia, europosła PSL Adama Jarubasa i dwóch doradców ministerstwa sprawiedliwości. Nieoficjalnie dowiadujemy się też, że w przyszłym tygodniu posiedzenie Sejmu może odbyć się w trybie zdalnym. Trwają też intensywne prace nad szczepionką. Kilka globalnych firm farmaceutycznych, między innymi Roche, Sanofi Pasteur i Johnson & Johnson, ogłosiło, że będą wymieniać się wynikami swoich badań i zasobami. Tymczasem prezes Polskiego Towarzystwa Wakcynologii Ernest Kuchar obawia się, że Polacy nie będą mieli szybkiego dostępu do szczepionki. Sposobem na szybsze uzyskanie szczepionki mogą być wspólne zakupy Unii Europejskiej. Prowadzi Karol Tokarczyk. Zapraszamy do słuchania.

Timur Akkurt'un bu hafta konuğu Dr. Emin Turan Sanofi Pasteur Türkiye ve Avrasya Bölge Başkanı. Konumuz aşı teknolojileri. Herkesin merak ettiği soruları ardı ardına Timur Akkurt sordu Dr.Emin Turan yanıtladı. - Aşı nasıl bulundu?- Dünya savaşlarında kaç kişi öldü? Aşı olmadığı için kaç kişi öldü?- Bir aşı ne kadar zamanda kullanılabilir hale geliyor? - Çok ciddi bir konu olan aşı geliştirmek için ne kadar para harcanıyor?- İçinde ne var? - Aşı karşıtlığı ne kadar gerçekçi bir yaklaşım? - Kimler aşı yaptırmalı? - Hangi hastalıklar aşı ile son buldu? - Hangi hastalıklar için aşı olmak zorundayız? - Kimler aşı yaptıramaz? Sizinde sorularınız varsa bize sosyal medya üzerinden ulaşabilirsiniz. Dr. Emin Turan ilerleyen podcastlerde düzenli olarak tekrar konuğum olacak. Dr.Emin Turan Linkedin hesabına ulaşmak için tıklayabilirsiniz.Timur Akkurt Instagram hesabına ulaşmak için tıklayabilirsiniz.Podcast Yayınlarımızı Düzenli Takip Etmek İçin Bizi Takip Edin!Spotify'da Dinlemek için TıklayıniTunes'da Dinlemek için TıklayınGoogle PodCast'te dinlemek için Tıklayın

Presented by Diane M. Birnbaumer, MD, FACEP To earn ACCME or ACPE credit, go online to scientiacme.org/cmecoursecontent.php?ID=278 to view the slides and complete the post-test. In this online CME self-learning program: Influenza has been recognized as a global public health menace since at least 100 years ago with the 1918-19 pandemic, which infected an estimated one-third of the world’s population and was responsible for the deaths of one in ten, or 50 million, of those infected. While some have contended that a significant number of deaths associated with the 1918 pandemic may have actually been attributable to acid-base derangements and pulmonary edema associated with contemporary aspirin dosing in the toxic range of two to eight times what is presently the maximum recommended dose – it remains a significant public health concern, with the 2017-2018 flu season in recent decades with an estimated 80,000 deaths (typical range 12,000-56,000 per year),coming with an annual cost of $16 billion. This program is supported by an educational grant from Sanofi / Pasteur. Faculty Disclosure: Dr. Birnbaumer has no relevant financial relationships to disclose.  

Libby Znaimer is joined by Zoomer Squad panelists Peter Muggeridge, Senior Editor of Zoomer Magazine and David Cravit, Vice President of ZoomerMedia. Every Monday, our Zoomer Squad panel convenes for a discussion on the issues that matter to you. First of all, the flu season is upon us - the good news is that Ontario is the only province where the high dose vaccine is covered for people over 65. In Alberta, for example, only seniors in long-term care homes are offered the high-dose shot, even though it's recommended for all seniors. Everyone else has to pay $75, and that's if they can get their hands on it. It looks like the high-dose vaccine won't be available in Alberta and British Columbia until late November or early December, because producer Sanofi Pasteur has said it will supply provinces where it is covered by health insurance first. Last week, Health Minister Christine Elliott said an additional 200,000 doses have been ordered this year. Share your thoughts on this topic with Libby and guests. Listen live, weekdays from noon to 1, on Zoomer Radio!

Change leadership presents challenges as Celine Schillinger, an expert on organizational change, corporate activism, and social networks, knows well. Celine discusses her experience working at pharmaceutical company Sanofi Pasteur, where she used the Kotter change model, social media, cross-hierarchy dialogue, and other change agent concepts to create a community of people who care for each other and facilitated the change process. Our conversation includes insights on the necessity of diversity. Join the conversation with  Celine Schillinger, CEO and founder of We Need Social. Listen to the Activate World Podcast Follow Activate World on Twitter Follow Activate World on LinkedIn

欢迎收听丽莎老师讲机器人，想要孩子参加机器人竞赛、创意编程、创客竞赛的辅导，找丽莎老师！欢迎添加微信号：153 5359 2068，或搜索微信公众号：我最爱机器人。丽莎老师讲机器人之AI改变现代商业的25种方式（下）。17、升级客服中心IBM 估计，到 2020 年，85％的客服工作将不再交由人工处理。机器学习和 NLP 技术让聊天机器人成为可能，自助服务界面就能帮助完成绝大多数人类客户代表的工作。那么，美国 270 万客户服务代表该怎么办？有些可能会从事机器人无法完成的任务（比如与真正愤怒的客户打交道）。依赖这项技术的公司表示，这些技术可以帮助消除人为错误，大幅提高数据检索的速度，并消除客户工作中的偏见。但不要认为这样的聊天机器人就是最终状态。瑞士投资银行瑞银（UBS）最近与新西兰人工智能专家 FaceMe 合作，数字化地克隆了首席经济学家丹尼尔·卡尔特（Daniel Kalt），让「他」与客户互动。该银行表示，这个虚拟人物使用了 IBM Watson AI 技术，并由 Kalt 本人训练过，这也是「人与数字混合」探索项目的一部分。18、发掘可能会被人们忽视的人才。安大略冰球联盟 19 岁的防守队员肖恩-杜尔兹就是一个例子。杜尔兹是今年国家冰球联盟（NHL）选拔赛的热门选手。但是在去年的选拔赛上，顶级球队并没有录用他，但人工智能支持的分析系统将他排在前 40 强。「如果这些球队去年查看了我们的系统分析的结果，那么它们可能早就会录用他了。该公司的人工智能系统已有 24 个 NHL 球队使用。Sportlogiq 只是使用 AI 帮助团队发现下一个明星的几家公司之一。这一切都是为了识别隐藏在口袋中的人才，发现金子。该公司曾与多家美国职业棒球大联盟球队合作，甚至为 2017 年环法自行车赛开发了一套机器学习 AI 系统，收集实时数据点，预测比赛结果。布鲁克林动力公司 正在开发一款应用程序，球探、教练可以对潜力和现有球员进行机器学习分析，j 借此打造一个全球大学和职业球队都可以查阅到的中心数据库。可以将这个独特的工具添加到人才储备工作中，其他人也可以查看 [统计数据] 并加入讨论，最终决定谁将为俱乐部带来价值。19、改变你的购物方式实体店面现在有了一个新的使命：完美的 AI 数据收集实验室。Home Depot 正使用来自数百万笔交易的数据，弄清楚你还有什么其他需求。丝芙兰使用 ModiFace（最近被 收购）的技术进行面部识别，帮助购物者选择合适的高光化妆品：该软件分析了数百万用户数据，可以更好地预测适合用户的产品。MIT 剥离出去的创业公司 Celect 正使用机器学习来预测购物者的行为方式，以确定在商店的哪个部分进行什么样的促销，效果更好，哪些产品放在哪里，会获得最佳效果。例如，沃尔玛已经在 50 家商店使用机器人，负责扫描货架上的缺货商品，被客户放错位置的商品，以及价格被标记错误的商品。对于人类来说，这些都是耗时且繁琐的工作。20、改变广告命中率越来越多的公司依靠人工智能来降低错失目标的可能性。情感识别的人工智能创业公司表示，财富 500 强企业中的四分之一正在使用他们的技术，比如在调研中利用人工智能来了解观众对广告的反应。Affectiva 的系统已经接受了来自 87 个国家的 700 万张面孔（以及 38 亿个面部框架）的图像训练，可以解码个人的面部表情。比如，在观众看到广告的那一刻起，识别出八种面部情绪，包括「厌恶」。媒体研究巨头也部署了这种产品。他们发现，美式橄榄球明星代言的广告引发微笑的程度值得注意，我们确实能够确定，明星传递的那种牺牲和梦想的信息引发了观众积极的反应，」他们还发现，观众对世界杯广告中的女性代言人做出了积极回应，这个发现有些出乎意料。除了帮助客户提升广告效果，系统还从中获得了能让所有客户受益的一些洞见。比如，主角是现代人物（而不是传统角色）的广告，其推广效果会提高 25％。21、种植食物表面上看，农业似乎就是简单苦力活儿的不断重复：播种、灌溉、收获。其实，如何种植作物非常复杂。「农业中要处理的大量数据，非常复杂，比如环境因素中的气流，二氧化碳，光照和湿度等因素、植物遗传以及施肥浇水等因素，都属于会相互作用的变量。现在，Plenty 和许多其他创业公司正在使用人工智能来协助做出复杂决策。例如，Plenty 及其对手都在打造用于收集和分析图像数据集的系统，帮助确定某株作物是否存在诸如氮或铁缺乏或虫害问题，提前进行治疗。软件了解问题所在，还可以进行大规模自动化处理，仅靠我们，无法单独完成。AI 正从三个方面变革医疗22、医疗保健制度再度人性化当前的美国医疗保健行业情况非常糟糕：每年，严重误诊次数超过 1200 万次，3.6 万亿美元医疗花费中的三分之一都归于浪费，预期寿命连续三年下降（史无前例），医生的职业倦怠、抑郁和自杀达到历史最高水平。但也因为有了可穿戴传感器生理学，扫描解剖学，DNA 测序，肠道微生物组生物学等，如今每个人的医疗数据比以往任何时候都多。有了深度学习，借助神经网络，人工智能将影响所有临床医生：从协助准确读取扫描，幻灯片，皮肤病变等，到保健系统、促进远程监控的使用，最终我们不再需要正规病房。而且借助虚拟医学指导，消费者就能更好地管理甚至预防疾病。虽然人工智能融入医疗实践，还处于早期阶段，当前是炒作胜过有效验证。但是，这是我们应对所有严峻挑战的最好机会：利用丰富的数据来减少误诊和浪费，并节省时间，显着改善医生与患者之间的关系。23、比医生更聪明仅在过去几年，就出现了一些比较靠谱的 AI 应用。比如读取放射扫描（如 Imagen），识别肿瘤并跟踪癌症扩散（Arterys），根据视网膜成像检测眼部状况（谷歌的 DeepMind），通过「不流血的血液测试」标记危险的异常钾水平（Mayo Clinic Ventures 和 AliveCor），以及其他帮助解决诊断棘手之处的应用，甚至包括预测疾病。历史数据表明，医生的误诊率在 5％到 20％，在某些情况下，这个数字更高，主要原因还是在于医生短缺和过度劳累，医疗保健系统资源紧张，因此，AI 或许可以帮助治疗一些疾病。24、重塑药物研发医药业充满变数。早期小规模病人测试中，如果药物是安全的，接下来还要进入烧钱的大规模临床测试阶段。事实上，德勤数据显示，2017 年美国最大的生物制药公司的投资回报率下降至令人沮丧的 3.2％。这就是为什么像 BERG 和 Roivant Sciences 以及 Exscientia 这样的公司希望利用 AI 更好地部署资源。BERG 已经与阿斯利康（AstraZeneca）和赛诺菲巴斯德（Sanofi Pasteur）等主要制药公司合作，使用临床数据和算法来识别潜在可能的生物靶点，研发有效药物以治疗帕金森等疾病。赛诺菲还在分析大量数据，以深入了解为什么某些流感疫苗对某些人有效，而对其他人无效。人工智能作为一种重要的药物研发工具，仍处于早期阶段。但前景光明：通过将制药研发工作转移到最有希望的靶点上，可避免大量浪费，如果药物研发能够更加精简，公司和患者都将受益。25、逆转疾病美国的医疗保健系统并未将更经济、更强调主动预防的方法放在优先考虑的地位，也因此遭受到大众的批评，企业也为失去劳动力和高昂的医疗成本付出代价。某公司利用人工智能，预防患糖尿病风险的患者进一步恶化疾病，在早期试验中，他们甚至尝试通过纯粹的数字平台，逆转 糖尿病。通过将用户与提供个性化饮食建议的虚拟指导联系起来，这家创业公司希望可以改变患者的生活方式。公司还提供数字连接工具，帮助用户测量血糖、酮、血压和体重。

086 | Paving the way of the future      Welcome to another episode of Biotechnology Focus radio! This week Toronto got their socks knocked off by an announcement from Sanofi; a Chinese company expresses interest in some of Canada’s regenerative medicine technologies; the scope of clinical trials in Canada is divulged at the recent Clinical Trials Ontario conference; and Shana Kelley and her team from the University of Toronto use new technology to essentially ‘find a needle in a haystack’ when it comes to prostate cancer. Keep listening to hear the latest news of Canada’s biotech scene!  +++++  French company Sanofi announces one of their largest investments ever in a single building and knocks the socks off the Toronto life sciences community. Sanofi announces that they are investing €350 million (C$500 million) into their Toronto facility to significantly increase capacity to meet the growing demand for pediatric and booster vaccines and demonstrate their commitment to innovation and leadership in global health.  The announcement was held at Sanofi Pasteur’s Canadian headquarters in Toronto and was joined by the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development, and the Honourable Steven Del Duca, Minister of Economic Development and Growth.  Canada has a strong legacy in the research and development of vaccines. With this investment, Sanofi is renewing their longstanding commitment to making Canada central in the effort to protect and improve human health across the globe. Vaccines save three million lives every year and this new facility will be one step closer to a world where no one suffers or dies from a vaccine-preventable disease.  The new facility will allow Sanofi Pasteur, the vaccines global business unit of Sanofi, to meet the growing demand of five-component acellular pertussis (5-acP) antigen. The building itself is expected to be completed within three to four years, a year or two to get the quality management system up and running, and a year or two to do product development and testing. The site will be equipped to produce the antigens used in the diphtheria and tetanus vaccines.  Philippe Luscan, the executive vice president of Global Industrial Affairs, Sanofi says that this project is one of the most important investments for the Sanofi global industrial network. It demonstrates the continued commitment to manufacturing excellence and to better serving their vaccines portfolio to people all over the world.  ++++++  New opportunities are arising at every turn for the regenerative medicine community. Research is at the tip of the iceberg, but a company in British Columbia isn’t waiting for the ice to melt. RepliCel, a regenerative medicine company, has been developing autologous cell therapies to treat conditions linked to the deficit of healthy cells required for normal function and healing. Their cell therapies are designed to treat chronic tendinosis, UV-damaged or aged skin, and pattern baldness as an alternative method to surgery, pills, and chemicals.  Recently, YOFOTO, one of China’s largest health and wellness companies announced its intention to invest significant financial backing into the company to market RepliCel’s tendon repair and skin rejuvenation products –  and they are not the only one – Shiseido, another giant, has been developing RepliCel’s hair regeneration technology for the Asian market.  Last year hit significant milestones for the company with production of the first fully functioning prototypes of their next generation dermal injector that is optimal for the delivery of injectables into the skin. With patents already issued in the United States and in Europe, the functioning prototypes allow RepliCel to display the applications of the device with other potential partners as they move forward at finalising the mold for the commercial-ready devices.  Last year also saw new clinical data produced on all three biologics programs – thinning hair (androgenic alopecia), aging/sun-damaged skin, and chronic tendinopathy (Achilles Tendinosis). The phase 1 clinical data demonstrated overwhelming product safety and highly encouraging signals of product efficacy to regrow hair, rejuvenate skin, and regenerate tendon tissue.  In 2013, RepliCel executed a co-development and licensing agreement with Shiseido that covered all of Asia for their hair regeneration program. Now, with the potential for another deal emerging in Greater China, we have real opportunity to leverage these partnerships to be a leader in regenerative medicine platform across Asia.  According to Brad Loncar, who recently launched a China BioPharm Index Fund, following the success of his Cancer Immunotherapy Fund, the biotechnology and pharmaceutical sectors are headed for exponential growth in the next few years and cell therapies are a significant focus in Greater China where he believes they are “ahead of the curve”.  Indeed, last month, the Chinese government unveiled its Made In China 2025 industrial plan in which it laid out a strategy for revolutionizing the Chinese biopharmaceutical industry through major investments in the sector and its supporting infrastructure.  It is a very exciting time for RepliCel as they move forward with a CE mark for their device in Europe and their potential expansion in Asia, as well as refining their US strategy for the launch of their dermal injector. With fascinating development projects in queue and continuing to look for the right opportunities, there will be substantial progress that will come from this innovative regenerative medicine company in the near future.  ++++++  It would be too easy to say that the recent CTO 2018 Clinical Trials Conference was an immense success – but it was. A sold-out event with 400 people speaks for itself. It was held in Toronto at the Sheraton Centre Hotel over two days chalked full of intrinsic speakers and panels discussing clinical research, clinical trials, and patient engagement.  The first day brought wonderful opening remarks from the Honourable Reza Moridi, Minister of Research, Innovation and Science, and was followed by Brian Goldman as the morning’s keynote speaker.  Brian Goldman is an ER physician, author and radio broadcaster of CBC’s White Coat, Black Art but chose to direct his keynote towards clinical trials in the age of disruption. Disruptive innovation has become a powerful change in health care, amongst many other industries. He defined exactly what disruptive innovation was with recent examples and its potential implications in health care – clinical trials, big data, clinical research.  To kick off the first panel was Jason Field, president and CEO of Life Sciences Ontario as a moderator of the evolving clinical research environment. The panel facilitated discussion on how to adapt to changes and how patients, health care and the economy will be impacted now and in the future.  As the day progressed there were speakers touching on future strategies, why Canada has a health care system, the misalignment of evidentiary interests and clearing the path ahead. An engrossing one-on-one interview after lunch with Francis Plummer, professor of medicine and medical microbiology from the University of Manitoba about a lesson in preparedness and how his work with the Ebola vaccine was a prime example of pre-empting what may happen, so that when and if it does, society will have a cure or at least a way to face it.  Clinical trials simply do not happen without participants, so the second panel brought patients and caregivers of patients to the stage to share their stories and experiences. They brought to life what the health care community works for and to and their advice on helping others find and join a clinical trial was instrumental.  The second day did not disappoint. Robert Bell, Minister of Health and Long-Term Care gave the opening remarks and welcomed the keynote speaker Ken Getz, director of sponsored research programs and research associate professor from the Tufts Center for the Study of Drug Development. Coincidently, he was also the keynote speaker at the very first Clinical Trials Conference that CTO put on a few years back; allowing him to describe first-hand how much it had grown and the benefits and impact this conference has on the clinical trials environment. He examined the current global operating environment for clinical research and specific areas where patient engagement practices and initiatives are being implemented.  Patient engagement with clinical trials remains a hot topic and largely uncharted territory. The first panel explored these models of patient engagement to give a voice to patient perspectives, quality of life values, and treatment experiences so that the health care system can get access to the drugs patients need sooner and create more robust trials and outcomes.  Following that, Molly Shoichet, Ontario’s first Chief Scientist was the interviewee of the day and went into detail about Canada’s research strengths, her aspirations for Ontario and Canada, and the innovation economy.  The remaining panels covered current interests such as big data in healthcare to advance opportunity and mitigate privacy risks, and how to advance ways to streamline the conduct of clinical trials and make Ontario and Canada a better place to have them executed. They engaged the audience in fruitful discussions and answered many burning questions from the listeners.  The two days compressed a wealth of knowledge, aspirations, and innovative ideas for the future of clinical trials in Ontario and Canada and left guests with an eagerness to start down that road.  +++++  Researchers at the University of Toronto have developed an innovative technology to identify which patients might not respond to standard therapy for prostate cancer before it is delivered from a “liquid biopsy”.  Prostate cancer is the most common cancer in men (excluding non-melanoma skin cancers) and third leading cause of death in Canada, according to the Canadian Cancer Society 2017 statistics. While several viable treatment options for prostate cancer exist, many men affected with prostate cancer will not respond to first-line treatments.  Shana Kelley, a professor at the University of Toronto divulges that screening for drug resistance is key to improving treatment approaches for many cancers. It is important for patients not to be on a therapy that won’t help them and it’s also important for health-care systems to avoid, whenever possible, delivering ineffective treatments.  Creating an option for a “liquid biopsy” via a blood test instead of more invasive alternatives is a step in the right direction and will save time, money, and recuperation time.  Kelley, lead investigator on the study published in Nature Chemistry, explains how her team has advanced a completely new approach using magnetic nanoparticles with DNA capture probes on their surface that can target circulating tumour cells (CTCs) in blood samples to see if the cells contain biomarkers associated with drug resistance.  The team traps the individual magnetized cells in a microfluidic device built in the lab, isolating them from all the other cells in the sample and allowing them to perform highly sensitive analysis. The cells with the highest magnetic content will also have a high messenger RNA expression for the biomarker associated with drug resistance. This means that patients with high messenger RNA expression should be considered for other therapies because they won’t respond to the first-line treatment.  Being able to access the circulating tumour cells  CTC cells is critical in the fight against cancer, as they carry information from the primary tumour that will divulge the best form of treatment for the patient. They are, however, outnumbered by a billion-to-one by normal cells in a patient’s blood making catching them a very daunting task.  In 2016, Kelley and her team published a study in Nature Nanotechnology that first introduced the microfluidic device and how it could be used to trap and analyze circulating tumour cells CTCs. The current study builds on this work by further targeting a specific biomarker within the circulating tumour cells CTCs.  The blood samples analyzed were collected from a small cohort of patients undergoing treatment for metastatic prostate cancer. In 10 of the patients tested, circulating tumour cells CTCs were visualized but only four of the patients exhibited the biomarker associated with drug resistance. This finding demonstrates that the new method can provide both a circulating tumour cells  CTC count and an analysis of the clinically relevant biomarker.  “We are very excited because this is like finding a needle in a haystack,” says Kelley. “It paves the way for a straightforward and personalized screening tool that allows clinicians to see if a patient will respond to therapy or not. Our method is also rapid, accurate and inexpensive, which gives it real potential for clinical uptake.”  Further studies need to be conducted to ensure consistent findings. Kelley and her team would also like to take this technology and expand it to other forms of cancer and disease.  ++++++  Well that’s it for another episode of Biotechnology Focus radio! To read the stories in full check out our website at biotechnologyfocus.ca. Thank you for listening and have a great week ahead! From my desk to yours – this is Michelle Currie.        

*Attendez,* *Resonance Test* fans! Céline Schillinger, Head of Innovation and Engagement at Sanofi Pasteur, injects some Gallic intelligence and passion into this episode of the podcast. Schillinger is all about enabling *quality,* the full intelligence and autonomy of the people in her organization. She is about healing a system, from a human-centric and social movement perspective. Listen as she and Continuum SVP Jon Campbell talk about how W. Edwards Deming has been misunderstood, the philosophical side of innovation capability, the challenges of behavior change, the workforce of the future, and what it's like for her to have won the *Ordre National du Mérite* (yes, she is a *knight!*). *Ecoutez,* and you'll hear mots such as: • "We have found that quality works better when it comes from people. When it comes from people's desires, when it comes from them and their head and their heart." • "My work is about having people regain their full intelligence." • "We can no longer rely on a system that has a small brain and many, many hands. We need the brain to be present in every cell of the organization." • "We are not just doing a job. We are fighting for something." • " When you give up control, you actually reduce risk." • "We need to work with more people who don't share our ideas, and yet we need to work towards a common goal." Host: Pete Chapin Editor: Kyp Pilalas Producer: Ken Gordon

En el programa de hoy conversamos con el Dr. Jaime Torres, Jefe de la Sección de Infectologia del Instituto de Medicina Tropical de la Universidad Central de Venezuela , quien pone en perspectiva y explica la controversia surgida con la vacuna del dengue de la compañía Sanofi Pasteur (Dengvaxia). Referencias: Luis Villar y colaboradores. Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America. N Engl J Med. Jan 8, 2015.    S.R.  Hadinegoro. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N Engl J Med.  Sep 24, 2015. Sanofi Pasteur. The first vaccine against dengue. OMS. Preguntas y respuestas sobre las vacunas contra el dengue. Sanofi Pasteur (2017). “Sanofi updates information on dengue vaccine”  World Health Organization (2017). “Updated Questions and Answers related to information presented in the Sanofi Pasteur press release on 30 November 2017 with regards to the dengue vaccine Dengvaxia”  Scott B Halstead. Critique of World Health Organization Recommendation of a Dengue Vaccine. J Infect Dis. Dec 2016. Scott B Halstead. Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age.  Vaccine. Nov 7, 2017.  

Sanofi Pasteur, one of the leading vaccine manufacturers in the world, is in the midst of its Phase III clinical trial called Cdiffense to study its investigational vaccine to prevent Clostridium difficile infection (CDI). The trial is now in more than 20 countries across 5 continents to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary, symptomatic CDI. The investigational C. diff vaccine is designed to produce an immune response that targets the toxins generated by C. diff bacteria, which can cause inflammation of the gut. The investigative vaccine ultimately may help prevent a future infection from occurring. Volunteers for the study should be age 50 or older and planning an upcoming hospitalization or have had at least two hospital stays and have received systemic antibiotics in the past year. For more information on the Cdiffense trial, please visit www.Cdiffense.org

Sanofi Pasteur's Dr. Christian Felter, MD is Associate VP, Global Medical Expert for Nosocomial Vaccines for Sanofi Pasteur based in Lyon, France. His focus is on their investigative Clostridium difficile vaccine. Dr. Patricia J. Freda Pietrobon, PhD, Associate Vice President, R&D, Sanofi Pasteur, has over 25 years of experience in the Vaccine & Diagnostic industries and more then 20 years in leadership roles focusing on research & development of new vaccines. Dr. Guy de Bruyn, Director for Clinical Development at Sanofi Pasteur, overseeing a large phase III vaccine trial for the prevention of Clostridium difficile infection in some 19 countries on 5 continents around the world that started in the U.S. in 2013. These three Sanofi Pasteur professionals will discuss the background of acquiring a C.difficile infection, Sanofi Pasteur's vaccine (Cdiffense) program, and the data from the preventative vaccine in Phase II.

Do you know what it really takes to get a Research Scientist position in industry? Do you know if this position is good fit for you? In this episode of the Industry Careers for PhDs podcast, we interview Vadim Khaychuk, Ph.D., an industry Research Scientist with experience at leading biotechnology and biopharmaceutical companies such as Sanofi Pasteur.

Sanofi Pasteur, one of the leading vaccine manufacturers in the world, is in the midst of its Phase III clinical trial called Cdiffense to study its investigational vaccine to prevent Clostridium difficile infection (CDI). The trial is now in more than 20 countries across 5 continents to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary, symptomatic CDI. The investigational C. diff vaccine is designed to produce an immune response that targets the toxins generated by C. diff bacteria, which can cause inflammation of the gut. The investigative vaccine ultimately may help prevent a future infection from occurring. Volunteers for the study should be age 50 or older and planning an upcoming hospitalization or have had at least two hospital stays and have received systemic antibiotics in the past year. For more information on the Cdiffense trial, please visit www.Cdiffense.org

Belén Garijo, Member of the Executive Board of Merck KGaA, Darmstadt, Germany, and CEO Healthcare, on Tuesday February 9. Dr. Garijo’s session was entitled “From Physician to CEO: Leadership Insight for Success.” Belén Garijo is a Member of the Executive Board of Merck KGaA, Darmstadt, Germany, since January 2015. She is responsible for the Healthcare business sector, comprising the businesses of Biopharma, Consumer Health, Allergopharma and Biosimilars. Since 2013 she also acts as President and CEO of Biopharma, where she started in 2011 as Chief Operating Officer. Before joining Merck KGaA, Darmstadt, Germany, Belén Garijo was employed by Sanofi-Aventis as Senior Vice President Global Operations Europe, serving as a member of the Management Committee of the Sanofi-Aventis Group and of the Management Board of the Sanofi-Pasteur vaccines joint venture with MSD. In 2011, she took on the additional role of Global Integration Leader for the Genzyme acquisition. From 2003 to 2006, Belén Garijo was General Manager of Aventis Spain, subsequently leading the merger of Sanofi-Aventis in 2004. From 2000 to 2003 she served as Global Vice President Oncology at Aventis and from 1996 as Director of the Oncology Business Unit in the predecessor company Rhône-Poulenc Rorer. Prior to this she worked in R&D for eight years, initially as the Medical Director of the Abbott Laboratories Spanish affiliate, before moving to lead International Medical Affairs at the Abbott headquarters in Illinois, USA. Belén Garijo is a medical doctor, specialized in clinical pharmacology. She worked as a practicing physician for six years, before moving to the pharmaceutical industry. Belén Garijo is married and has two daughters.

In episode two, I am delighted to be joined by Celine Schillinger, who is Head, Innovation & Engagement for Quality at Sanofi Pasteur as well as a charter member of Change Agents Worldwide. We discuss her ground-breaking work in leading change at a traditional pharmaceutical organisation, her experiences of working over three continents, and her tips for overcoming objections.

Ce matin, Emmanuel Duteil salue la recherche médicale française à travers un exemple : le tout premier vaccin contre la dengue dont l'autorisation de mise sur le marché a été donnée cette semaine par Sanofi Pasteur.

Sanofi Pasteur's Dr. Christian Felter, MD is Associate VP, Global Medical Expert for Nosocomial Vaccines for Sanofi Pasteur based in Lyon, France. His focus is on their investigative Clostridium difficile vaccine. Dr. Patricia J. Freda Pietrobon, PhD, Associate Vice President, R&D, Sanofi Pasteur, has over 25 years of experience in the Vaccine & Diagnostic industries and more then 20 years in leadership roles focusing on research & development of new vaccines. Dr. Guy de Bruyn, Director for Clinical Development at Sanofi Pasteur, overseeing a large phase III vaccine trial for the prevention of Clostridium difficile infection in some 19 countries on 5 continents around the world that started in the U.S. in 2013. These three Sanofi Pasteur professionals will discuss the background of acquiring a C.difficile infection, Sanofi Pasteur's vaccine (Cdiffense) program, and the data from the preventative vaccine in Phase II.

Sanofi Pasteur's Dr. Christian Felter, MD is Associate VP, Global Medical Expert for Nosocomial Vaccines for Sanofi Pasteur based in Lyon, France. His focus is on their investigative Clostridium difficile vaccine. Dr. Patricia J. Freda Pietrobon, PhD, Associate Vice President, R&D, Sanofi Pasteur, has over 25 years of experience in the Vaccine & Diagnostic industries and more then 20 years in leadership roles focusing on research & development of new vaccines. Dr. Guy de Bruyn, Director for Clinical Development at Sanofi Pasteur, overseeing a large phase III vaccine trial for the prevention of Clostridium difficile infection in some 19 countries on 5 continents around the world that started in the U.S. in 2013. These three Sanofi Pasteur professionals will discuss the background of acquiring a C.difficile infection, Sanofi Pasteur's vaccine (Cdiffense) program, and the data from the preventative vaccine in Phase II.